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AToPic derMATiTis – GenerAl bAckGround oF THe diseAse
Atopic dermatitis (AD) is the most common inflammatory skin disease, which mainly af-
fects children. The prevalence of childhood AD is up to 25% compared to 2-10% in adults.1-3 
The hallmarks of AD are intense itching and a dry skin with recurrent heterogeneous 
eczematous lesions, including erythema with scaling, exudation, blistering, crusting, fis-
suring and/or lichenification.4, 5 The eczematous lesions can be present at any part of the 
body, but mostly show age related distribution that can be roughly subdivided in three 
stages: infancy, childhood and adolescence/adulthood.6 Bacterial and viral infections are 
common complications in AD skin.7 Especially more severe AD is associated with diseases 
of the atopic syndrome that include food allergy, asthma and allergic rhinitis.8, 9 Further-
more, AD has a significant impact on the quality of life, particularly due to effects on social 
functioning and the psychological well-being.10, 11
Both genetic and environmental factors are implicated in the development of AD. As AD is 
highly heritable (approximately 75% in a twin study), the strongest risk factor is a positive 
family history for atopic diseases, especially for AD.12, 13 In past genome-wide association 
studies (GWAS), 34 risk loci associated with AD were identified.14 These loci account for 
less than 20% of the heritability and are mainly involved in the skin barrier function and 
immune response pathways.14 The inherited susceptibility is triggered by environmental 
and lifestyle-related factors. Important exposures associated with AD include climate, 
socio-economic status, housing conditions, rural or urban living, diet and microbial expo-
sure.15, 16
The diagnosis of AD is primarily based on clinical features.17 To create more uniformity 
in this diagnosis, several diagnostic criteria for the use in clinical practice and population 
based studies have been developed.18-20 Particularly in non-responders to therapy, skin 
biopsy, laboratory testing, patch testing and/or genetic testing are used to rule out other 
disorders presenting with a dermatitis.17
AToPic derMATiTis – PATHoGenesis
The etiology of AD is multifactorial and not completely understood, with complex interac-





The human microbiome is the collection of all microbiota that reside on or within human 
tissues. Since next generation sequencing has become more available for microbiome 
analysis, our knowledge on microbial communities and even functional properties has 
grown. It was shown to have an important impact on the physiology and metabolism in 
humans.23 Both endogenous and exogenous factors (i.e., sex, age, climate and lifestyle) 
may modulate the microbiome, leading to a large interpersonal variation and variation 
over the lifetime of an individual.24, 25 Changes in the microbiome are associated with a 
wide array of diseases, including skin diseases as AD.
The skin microbiome is thought to play a role in both the pathogenesis and severity of the 
symptoms in AD.26 It has been proposed that there is a window in neonatal life in which 
exposure to certain microbes affects the development of both the innate and adaptive 
immune response and the tolerance against certain species, which plays a role in the 
susceptibility to diseases.27 This idea has arisen from studies showing a reduced microbial 
diversity and the presence of certain gut bacteria in the first days of life in individuals 
developing atopy.28, 29 There is also recent evidence from mice studies for an effect of 
skin microbes in shaping the immune system.27, 30 These mice studies suggest that skin 
colonization with commensal bacterium in neonatal mice leads to less inflammation to 
these microbes upon re-challenging.27, 30 In addition, several studies in humans suggest 
Figure 1. Disease model of AD (illustration J.E.E. Totte22)
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that alterations in the skin microbiome in the early life of individuals are associated with 
an increased risk to develop AD.31, 32
Later in life, the skin microbiome contributes to the course of the disease. Especially the S. 
aureus bacterium is associated with AD. Both the lesional and nonlesional skin of patients 
with AD are highly colonized by S. aureus and show reduced bacterial diversity.26, 33 Analy-
sis of the skin microbiome shows a positive correlation between S. aureus colonization and 
disease severity, with increased S. aureus abundance during disease flares.33-36 A meta-
analysis including 95 observational studies showed that colonization rates for S. aureus 
on lesional skin, nonlesional skin and in the nose were 70%, 39% and 62%, respectively.37 
Although current data are not sufficiently robust, there is also evidence of other microbes 
involved in AD with reduced levels of the Cutibacterium and Malassezia species.38, 39
Although multiple studies have shown the correlation between an increase in S. aureus 
abundance and disease severity, it is not entirely known how this bacteria can lead to the 
AD characteristic inflammation.40, 41 The S. aureus bacterium can be present in humans 
both as a commensal organism and as a pathogen responsible for disease.42 S. aureus 
secretes a variety of enzymes, cytotoxines and exoproteins to convert host tissues into 
nutrients for bacterial growth and to inhibit host immune responses.43 Different strains 
of the bacterium carry a different combination of virulence factors and therefore it is 
possible that certain strains of this bacterium are more prone to cause AD.41 For a better 
understanding of the role for S. aureus in the pathogenesis of AD, it is crucial to gain more 
knowledge on the genetic background and behavior of this bacterium in patients with AD. 
In addition, exploring endogenous and exogenous factors that affect the skin microbiome 
might help in the development of future treatment strategies.
skin barrier dysfunction
The main function of the skin is the defense against environmental influences. The stratum 
corneum (SC) is the outermost layer of the skin and plays the most important role in the 
skin barrier function by preventing extensive water loss and penetration of environmental 
compounds (i.e., allergens, irritants, pathogens).44 Genetic and acquired defects in struc-
tural proteins, lipids and tight junctions (TJ) of the skin lead to an impairment in the skin 
barrier function as seen in AD.45
Mutations in the gene encoding the SC structural protein filaggrin (FLG) have shown to 
be the most important risk factor in the development of AD.46 FLG is located within the 
epidermal differentiation complex (EDC) on chromosome 1q12 and encodes profilaggrin, 
the precursor of the structural protein filaggrin.47 FLG consists of 3 exons of which the third 
is one of the largest exomes (>12kilobases) in the genome, including 10-12 repeat units 
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which are highly homologous.47 Filaggrin is essential for the construction and maintenance 
of the skin barrier function. This protein facilitates the binding and collapsing of keratin 
filaments, which helps in the mechanical strength of the SC.47, 48 Subsequently, filaggrin 
is degraded by proteases into hygroscopic amino acids and forms, together with specific 
salts and sugars, the largest part of the natural moisturizing factor (NMF). NMF plays an 
important role in skin hydration, maintenance of the skin pH and ultra-violet (UV) protec-
tion.49, 50 It was suggested that the concentrations of NMF in the SC of AD patients can be 
used as a proxy for the presence of FLG null mutations.50, 51
In AD patients, the prevalence of a mutation in FLG is up to 40%.47, 52 Distinct sets of FLG 
mutations are present in each population.53 For Western-European populations, 2282del4, 
R2447*, R501* and S3247* are commonly described.54 Carriers of a heterozygous loss-of-
function mutation in FLG have a 50% reduction in filaggrin expression, compared to a total 
loss of protein in homozygous and compound heterozygous carriers.55 Large longitudinal 
studies have shown that AD patients with a mutation in FLG have a more severe disease 
trajectory compared to wild-type patients.48 This group is characterized by early onset 
disease with persistence into adulthood with an increased risk to develop secondary 
allergic conditions (i.e., food allergies, asthma, and allergic rhinitis).56, 57 There is also 
recent evidence suggesting that patients with a primary skin barrier defect might have 
less benefit from systemic immunomodulatory treatment.58, 59 Therefore, determining  the 
presence of a mutation in FLG could be useful for early identification of the patients who 
might develop a more severe phenotype and for personalization of treatment. However, 
genotyping is time consuming, expensive and DNA collection poses ethical considerations 
and is therefore not used in daily practice.46, 60 As AD mostly affects children, non-invasive 
measurement of NMF concentrations in the SC as biomarker for FLG mutation status is of 
added value.
immunological changes
The immune response in AD is characterized by altered T helper (Th) cell activation. Three 
different immune phenotypes have been described for AD, including the nonlesional skin, 
disease flares (lesional skin) and the chronic AD skin.61 The nonlesional skin of AD patients 
shows an increased infiltrate of inflammatory T-cells compared to normal skin, which is 
mostly characterized by increased numbers of Th2, Th22 and Th17.61, 62 The combination 
of this pro-inflammatory state in nonlesional skin with the impaired skin barrier allows 
the penetration of environmental stimuli into deeper skin layers. This triggers the expres-
sion of pattern recognition receptors (PRRs) by keratinocyte and antigen-presenting cells 
(APCs) in the skin.6, 63 PRRs are innate immune receptors which form the first line of de-
fense mechanism to prevent microbial invasion and further tissue injury.63 PRRs recognize 
pathogen-associated molecular patterns (PAMPs) and in response to microbes or tissue 
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damage, PRRs release a broad range of inflammatory mediators, including cytokines, che-
mokines and anti-microbial peptides (AMPs).64 Keratinocyte-derived cytokines interleukin 
(IL)-25, IL-33 and Thymic stromal lymphopoietin (TSLP), promote Th2 cytokine responses 
either directly by Th2 cytokine expressing cells or indirectly via dendritic cell (DC) po-
larization.65 TSLP expression is positively correlated with disease severity in AD, which 
results in increased Th2 cell infiltration with the production of multiple pro-inflammatory 
cytokines, including IL-4, 13 and 31 in lesional skin.65 The chronic inflammation in AD skin 
is marked by a shift towards Th1 cell infiltration. This shift is supported by DCs secreting 
large amounts of IL-12 under the influence of Th2 cytokines or by the binding of S. aureus-
derived lipoteichoic acid to DCs.66 In turn, Th1 cells produce Interferon gamma (IFN-γ), 
which inhibits keratinocyte differentiation resulting in epidermal hyperplasia as seen in 
chronic AD lesions.67
Another important immunological feature in AD is the humoral immune response, char-
acterized by the presence of immunoglobulin (Ig)E. Upon penetration of allergens into 
the impaired skin barrier, the Th2-driven response leads to Ig-class switching in B cells to 
IgE.68 The presence of increased IgE levels against inhalant and food allergens are common 
among AD patients and even an increased IgE response against micro-organisms can be 
observed.69-71
interactions between the microbiome, skin barrier and immune system
Several models have been suggested to explain the etiology of AD, mostly referred to as 
the ‘inside-out’ (altered inflammation triggers barrier dysfunction, enabling the penetra-
tion of environmental stimuli) and ‘outside-in’ theory (skin barrier dysfunction allows 
penetration of stimuli to induce immune responses).72 Recently, both models have been 
proven of importance in AD, underlining the multidirectional interactions between the 
microbiome, skin barrier and immune response.73
The impaired skin barrier in patients with AD leads to an increased penetration of mi-
crobes. This association has been mostly investigated for FLG mutation status in relation to 
S. aureus colonization. The AD skin is characterized by decreased skin hydration, increased 
skin pH, altered keratinocyte adhesion properties and the activation of a number of serine 
proteases, leading to desquamation.74 The increased adhesion sites and the altered milieu 
on the skin is thought to enable the growth of different microbes than present on the 
healthy skin, leading to increased presence of S. aureus.74-77 In turn, the penetration of 
S. aureus into the epidermidis leads to the secretion of a number of molecules further 
enabling S. aureus colonization and skin barrier damage through direct effects or stimula-
tion of the immune system.74, 78 The direct skin barrier damage is caused by the cytolytic 
activity from S. aureus exotoxins and the ability of S. aureus to stimulate keratinocytes 
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to produce endogenous serine proteases.79, 80 S. aureus secreted enterotoxins acting as 
superantigens (Sags) can directly stimulate T-cell proliferation and recruitment to the 
skin.43 Activated Th2 cytokines IL-4 and IL-13 downregulate filaggrin expression, decrease 
sphingomyelinase (normally protecting against α-toxin induced keratinocyte damage), 
induce fibronectin synthesis and suppress the expression of AMPs.81 Furthermore, the 
expression of Th2 cytokine IL-31 leads to increased pruritus, resulting in further skin bar-
rier dysfunction and exposing extracellular matrix (ECM) adhesins for S. aureus binding.82
Less is known about the effect of FLG mutations on the complete microbiome composition 
and the immune cell numbers in patients with AD. Recently, one study investigated the skin 
microbiome in adult AD patients with FLG mutations and showed a different microbiome 
on nonlesional skin compared to wild-type patients.75 Current evidence for the association 
between FLG mutations and the immune cell composition come from a small number of 
AD case series, mice studies and one skin equivalent study.83-87 These studies suggested an 
increase in circulating Th2, Th17 and γδT17 cells as a result of FLG mutations.83-87
Complex interactions between the skin microbiome, skin barrier and immune system 
contribute to the inflammation in AD. It is likely that the role of each element differs 
per patient and even within a patient over time. Knowledge of the complex bidirectional 
interactions in the pathogenesis is important for a better understanding of this complex 
disease and to further develop targeted treatment.
AToPic derMATiTis – TreATMenT TArGeTinG THe MicrobioMe
The aim of treatment in AD is to improve symptoms and gain long-term disease control. 
Cornerstones in the treatment of AD are the use of emollients and trigger avoidance (i.e., 
irritants, allergens and stress).88 The mainstay of anti-inflammatory treatment includes the 
use of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), but in severe/
refractory cases the use of systemic immune suppressive treatment can be indicated.89, 90
Due to the association between S. aureus and AD, therapeutic strategies targeting the 
microbiome are being investigated. In current guidelines, short term use of oral antibiotics 
against S. aureus is indicated in clinically infected AD.91, 92 In recurrent infected AD, the use 
of topical antiseptics (i.e., povidone-iodine and chlorhexidine) are advised.92 The role of S. 
aureus is less clear in clinically non-infected AD and a Cochrane review found insufficient 
evidence on the benefit of anti-staphylococcal agents in these cases.93 However, this 
Cochrane review did not include long-term follow-up studies and as regrowth of S. aureus 
might occur quickly in patients with AD, long-term treatment might be beneficial.94 Since 
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continued use of anti-microbial treatment also affects commensal micro-organisms and 
might induce bacterial resistance, alternative treatments targeting the microbiome should 
be evaluated.95, 96 In this context, studying the effect of bacteriophages and bacteriophage 
lysins in eradicating S. aureus could be helpful. Bacteriophages are viruses that infect and 
replicate within their host and produce endolysins that digest the bacterial cell wall and 
selectively kill specific bacteria.97 It is important to gain more knowledge on the impact of 
currently available and novel treatments on the skin microbiome. This will lead to insights 
into the role of the microbiome in the pathogenesis and disease course of AD and improve 
current treatment strategies.
Aims oF This Thesis
The pathophysiology of AD is highly complex with a heterogeneous clinical presentation. 
Recent knowledge emphasizes that the skin microbiome, skin barrier and immune system 
are all interacting and together reinforce the process of inflammation in AD. However, not 
all interactions are thoroughly investigated and research on the impact of the impaired 
skin barrier, caused by FLG mutations, on the microbiome and immune cells is lacking 
and needs to be validated. Furthermore, most studies investigating the skin microbiome 
in patients with AD have used methods that are unable to classify microbes up to species 
level or to identify genetically distinct strains. Therefore, knowledge is lacking on how the 
S. aureus bacterium is able to cause symptoms of AD. Knowledge on the multidirectional 
interactions of the pathophysiological aspects and the role of S. aureus as aggravating fac-
tor will lead to a better understanding of this disease and help develop new personalized 
treatment strategies. In this thesis we aimed to fill some gaps in the current knowledge on 
the pathophysiology of AD. The specific aims are listed below:
- Gain more knowledge on the role of S. aureus in the pathogenesis of AD by investigat-
ing which strains of this bacterium are present over time in AD patients and interact 
with disease severity (chapter 2).
- Further investigate the bidirectional interactions between the skin microbiome, skin 
barrier and immune system by evaluating if mutations in FLG shape both the micro-
biome in AD (chapter 3.1) and circulating immune cells (chapter 3.2) in the general 
population and AD patients.
- Validate the use of measuring NMF content in the SC to stratify patients based on FLG 
mutations status to enable the identification of patients at high risk for a more severe 
phenotype and to enable personalized treatment (chapter 4).
- Study the effect of treatment interfering with the skin microbiome using alpine climate 
treatment (chapter 5.1) and a targeted intervention against S. aureus (chapter 5.2) in 
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patients with AD to further elucidate the role of the microbiome in the pathogenesis of 
AD.
sTudy desiGn
The research in this thesis was based on four study cohorts, including the DAVOS, MAAS, 
KinderHaven and Generation R cohort. The DAVOS cohort included 79 children with dif-
ficult to treat AD between the age of 8 and 18 years.98 This randomized controlled trial 
(RCT) was designed to investigate the short and long-term effectiveness of inpatient alpine 
climate treatment in comparison to an outpatient treatment setting in moderate maritime 
climate. Clinical data, microbial and DNA samples from this cohort were used to evalu-
ate the effect of alpine climate treatment on the composition of the skin microbiome on 
lesional and nonlesional skin. Furthermore, these data were used to evaluate the associa-
tion between a mutation in FLG and the microbiome. The MAAS cohort included 100 adult 
patients with clinically non-infected, moderate to severe AD who were participating in a 
RCT to evaluate the effect of a targeted intervention against S. aureus with topical endoly-
sin treatment (Staphefekt SA.100) on the usage of TCS.99 The S. aureus cultures that were 
collected during this trial also enabled us to determine the S. aureus genotypes present in 
AD patients, by characterizing S. aureus isolates with spa-typing. The KinderHaven cohort 
included 837 children (0-18 year) with AD that consulted the dermatologist in a pediatric 
multidisciplinary atopic expert center between 2016 and 2019. During their visit, the NMF 
content in the SC was measured using Raman Spectroscopy. In addition, DNA samples (us-
ing buccal swabs) were collected from 101 children to detect mutations in FLG. With these 
data we could determine the value of NMF as a biomarker for FLG mutation status. Finally, 
the Generation R study is a population-based prospective birth cohort study following 
children from their early fetal life onwards.100 Data from 523 children in this cohort (DNA 
samples and immune cell numbers) were used to determine the effect of FLG mutations 
on the B -and T-cell subsets (at the age of 10 years) in children of the general population 
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Staphylococcus (S.) aureus colonization is associated with increased disease severity in 
patients with atopic dermatitis (AD).
objective
To investigate temporal variation in S. aureus spa-types isolated from the nasal cavity and 
lesional skin, and the correlation of spa-types with disease severity.
results
This study included 96 adult AD patients who were assessed at baseline (T0) and after 
a strict two week follow-up period (T1) in which treatment was standardized with topi-
cal corticosteroid. Fifty-five different spa-types were detected within the nose and skin 
cultures. Seventy-three patients were colonized with S. aureus in the nasal cavity at both 
time points (persistent carriership) of whom 59 (81%) had identical spa-types over time. 
For skin samples, 42 (75%) of the 56 persistent skin carriers had identical spa-types over 
time. Patients carried the same spa-type in nose and skin in 79% and 77% at T0 and T1, 
respectively. More severe disease was not associated with specific spa-types nor with 
temporal variation in spa-type.
conclusion
S. aureus strains in AD are highly heterogeneous between patients. The majority of pa-
tients carries the same spa-type in the nose and on the skin without temporal variation, 
suggesting clonal colonization within individual patients. No predominant spa-type nor 
temporal variation is associated with increased disease severity.
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inTroducTion
Atopic dermatitis (AD) is the most common inflammatory skin disease with a lifetime 
prevalence of 15—20% and a significant negative impact on the quality of life.1 The patho-
genesis of AD is multifactorial, involving skin barrier defects and immunological dysregula-
tion.2 Moreover, strong evidence links the skin microbiome, characterized by an increased 
abundance of Staphylococcus (S.) aureus and less bacterial diversity, to the pathogenesis 
and disease severity in this patient group.2-6
S. aureus is both a human commensal organism and a pathogen.7 The most frequent 
carriage site is the nose, which is assumed to be the main reservoir for the spread of S. 
aureus associated with skin infections.7, 8 Approximately 20% of the general population is a 
persistent carrier of S. aureus in the nose.9 Cross-sectional data in AD showed that 62% of 
the patients was colonized in the nasal cavity, compared to 70% on lesional skin.3
The association between S. aureus colonization and disease severity has been thoroughly 
investigated, however the underlying mechanisms resulting in AD characteristic inflam-
mation remain unclear.10 It is challenging to understand which specific strains can cause 
inflammation as it can carry a wide diversity of virulence factors enabling transmission, 
virulence and antibiotic resistance.11 It was proposed that the immunologic response 
varies depending on the isolated strain.12 In addition, temporal variation in colonizing S. 
aureus strain might aggravate the symptoms in AD due to a new trigger that is introduced 
to the immune system.13, 14 This emphasizes that strain differences may contribute to the 
complexity of the disease, encouraging a more extensive investigation into the S. aureus 
populations in AD.
Multiple molecular identification methods are available for discriminating among S. aureus 
isolates. Spa-typing is a single-locus typing technique which offers a subtyping resolution 
comparable to more expensive and laborious techniques such as multilocus sequence typ-
ing (MLST) and pulsed field gel electrophoresis (PFGE).15 The spa-typing technique targets 
the polymorphic region of the S. aureus-specific staphylococcal protein A (spa) gene. The 
encoding region consists of a variable number of repeats with highly variable nucleotide 
sequences.16 Since it is sequence-based, the results produced in different labs are easily 
comparable.
Literature on the temporal variation of S. aureus and the association with disease severity 
is scarce. Due to low patient numbers with multiple treatment regimens and the absence 
of a strict follow-up time, results are subject to confounders.13, 14, 17 This study investigates 
temporal variation in S. aureus spa-types in adult AD patients with a strict follow-up period 
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of two weeks in which treatment was standardized with topical corticosteroids (TCS), 
which reduced possible confounding of the comparisons over time. Furthermore, we as-
sess similarities in spa-types from nose and skin and its correlation with disease severity. 
Knowledge of the colonization patterns of S. aureus in AD contributes to the development 
of new strategies to improve inflammation in AD.
MATeriAl And MeTHods
study design
This was a longitudinal study embedded in the MAAS trial (ClinicalTrials.gov NCT02840955). 
Details of the clinical trial and primary outcome have been published previously.18, 19 For 
our current study we included measurements from time point 0 (T0, baseline) and time 
point 1 (T1). T1 was scheduled after a two-week run-in period, in which treatment was 
standardized with triamcinoloneacetonide 0.1% cream according to a corticosteroid 
dosing regimen. Study procedures were reviewed and approved by the Medical Ethics 
Committee of the Erasmus MC University Medical Center Rotterdam, the Netherlands 
(MEC-2016-233). Signed informed consent was obtained from all participants.
study population
Adult patients (≥18 years) with moderate to severe AD, according to the UK working party 
diagnostic criteria for AD, defined by an Eczema Area and Severity Index (EASI) score of 7.1 
to 50.0, were eligible for participation in the study.20 Other inclusion criteria were the use 
of any TCS before enrolment and the ability to read and understand the patient informa-
tion. Patients were ineligible for participation if they used systemic antibiotics or systemic 
corticosteroids in the previous two months, oral immunosuppressive agents or ultraviolet 
light therapy in the previous three months, or topical antibiotics in the previous week. An-
other exclusion criterion was the presence of another skin condition that could interfere 
with the assessment of the AD severity. Patients were characterized by demographic data 
and disease severity was assessed at both time points by the research physician using the 
EASI score. Based on the continuous EASI score, patients were categorized in almost-clear, 
mild, moderate or severe disease as described previously.21
sample collection and S. aureus typing
Samples for culture analysis were collected using sterile dry Copan 490CE swabs, which 
were transferred into liquid Amies medium after collection. Skin swabs were collected 
from the lesional skin, preferably located at the antecubital fold or the popliteal fold at 
T0. These lesions did not show any signs of impetigo. At T1, the skin swab was collected 
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from the location chosen at T0. Nose swabs were collected from both the anterior nares 
at T0 and T1.
Bacterial semi-quantitative cultures were performed using routine diagnostic culture pro-
cedures, using blood agar plates and specific S. aureus culture plates (ChromID S. aureus 
Elite agar (SAIDE), Biomérieux, France). Plates were incubated at 35°C and growth was 
assessed after 1 and 2 days of culture. Subsequent species determination by MALDI-TOF 
(Bruker Daltonics, Bremen, Germany) was performed. For each distinct colony morphology 
of S. aureus in a sample, a representative colony was picked to store the strain at -20°C for 
future analysis. The semi-quantitative S. aureus cultures were reported on a categorical 
scale ranging from 0 (negative) to 4 (strongly positive).
DNA was extracted from the collected S. aureus isolates using a MagNA Pure 96 platform 
in combination with the MagNA Pure DNA and Viral Nucleic Acid Small Volume Kit (Roche 
diagnostics, Almere, the Netherlands). PCR reactions were performed in 25 µl reactions 
using 1 µL of isolated DNA in 1x FastStart PCR Master (Roche) and 0.5 µM of both forward 
primer (5’-AACAACGTAACGGCTTCATCC-3’) and reverse primer (5’- GCTTTTGCAATGTCATT-
TACTG-3’). Thermal cycling consisted of an initial denaturation step for 10 min at 95°C 
followed by 35 cycles of 30s at 95°C, 30s at 60°C and 1 min at 72°C. After a final extension 
step of 10 min at 72°C, reactions were cooled to room temperature. Five µl of PCR product 
was analyzed on agarose gel to confirm amplification. The remainder of the PCR product 
was treated with 2 µL of ExoSAP-IT (Isogen Life Science, De Meern, the Netherlands) for 15 
min at 37°C following inactivation for 15 min at 80°C. Amplicon sequencing was performed 
by BaseClear (Leiden, the Netherlands) using the forward amplification primer as sequenc-
ing primer. Electropherograms were analysed and interpreted using the spa-typing plugin 
in BioNumerics v7.6 software (Applied Maths, Sint-Martens-Latem, Belgium).
statistical analysis
Descriptive statistics were used to present patient and sample characteristics. Persistent 
nose and skin carriers were defined as patients with a positive S. aureus culture at both 
time points for nose or skin, respectively. Intermittent carriers were defined as having 
a positive S. aureus culture at only one time point (T0 or T1), either in nose or skin. For 
the difference in EASI score over time, a Wilcoxon Signed Rank test was used. A Mann-
Whitney U test was performed to determine the differences in EASI score for S. aureus 
colonization and temporal variation in spa-type. The S. aureus load, as determined by 
semi-quantitative culture, between both time points was tested using a Chi-square test. 






A total of 100 patients were eligible for participation in this study. From 96 patients bacterial 
cultures were available at both time points and therefore included in this study. The median 
age was 32 years (interquartile range (IQR) 25—47) and 45 patients (47%) were female. The 
median EASI score at T0 was 13.1 (IQR 9.4—19.0) compared to 8.1 (5.0—13.8) after the two-
week run-in period with triamcinolone (p<0.01) (Table 1). As shown in Table 1 and Figure 1, 
we found high colonization rates in both nose and skin and both time points.
A heterogeneous S. aureus among Ad patients, but identical spa-types in the nose 
and on the skin
Of the 290 positive S. aureus cultures (nose T0: 79; nose T1: 78; skin T0: 71; skin T1: 62), 
285 isolates were available for spa-typing. All S. aureus positive cultures contained only 
one distinct morphological colony type of S. aureus. Fifty-five different spa-types were 
found, with t002 (10%), t091 (8%), t127 (8%), t571 (7%) and t189 (6%) as the most com-
mon, accounting for less than 40% of all spa-types. Figure 2 shows the prevalence of the 
10 most common spa-types separated for nose and skin. The spa-types that were identi-
Table 1. Patient characteristics
Total (n=96)
Age, median (iQr) 32.0 (25.0—47.0)
Female, n(%) 45 (46.9)
race, n (%)
American or Alaska native 5 (5.2)
Asian 10 (10.4)





Positive for S. aureus noseb, n(%)
T0 79 (82.3)
T1 78 (81.3)
Positive for S. aureus skinc, n(%)
T0 71 (74.0)
T1 62 (64.6)
Abbreviations: EASI, Eczema Area and Severity Index; IQR, interquartile range; T0, baseline. T1, two weeks 
after baseline. aEASI score ranges from 0—72. b73 patients (76.0%) were colonized in the nasal cavity at both 
time points. c56 patients (58.3%) were colonized on the skin at both time points.
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fi ed in our study populati on were also present in previously investi gated AD populati ons 














Figure 1. Temporal S. aureus colonizati on
Of the 84 pati ents positi ve for S. aureus at baseline, 66 pati ents (79%) were positi ve in the nasal cavity and 
skin, 13 pati ents (15%) were positi ve only in the nasal cavity and 5 pati ents (6%) only on skin. Of the 81 pa-
ti ents positi ve  for S. aureus at T1, 59 pati ents (73%) were positi ve in the nasal cavity and skin, 19 pati ents 
(23%) positi ve only in the nasal cavity and 3 (4%) positi ve only on skin. Abbreviati ons: n, number; T0, baseline; 























Figure 2. Frequency of the 10 most common spa-types per locati on and ti me point
The 10 most common spa-types in the nose samples at T0, represent 48.1% of the total spa-types. For the 
nose samples at T1, the 10 most common spa-types represented 53.8% of the total. For the skin samples at 
T0 and T1, this was 61.9% and 59.8%, respecti vely. The overview of all spa-types is represented in Figure S1. 
Abbreviati ons: T0, baseline; T1, two weeks aft er baseline.
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Sixty-six patients had positive S. aureus cultures in both nose and skin at baseline, includ-
ing 79% (52/66) with identical spa-types at both locations. At T1, the group of patients 
positive at both sample locations included 59 patients, of whom 78% (46/59) carried the 
same spa-type.
High prevalence of persistent S. aureus carriers in the nose and on the skin with 
identical spa-types
Our study population comprised 76% (73/96) persistent and 11% (11/96) intermittent 
nose carriers. 80% (59/73) of the persistent nose carriers were colonized with the same 
spa-type during follow-up. On AD skin, 58% (56/96) patients were persistent carrier and 
22% (21/96) intermittent carrier. Within the group of persistent skin carriers, 79% (44/56) 
had identical spa-types over time.
disease severity is not associated with the spa-type present in the nose and on the 
skin
Patients who were positive for S. aureus (nose and/or skin) at baseline had a significantly 
higher EASI score at T0 compared to patients who were negative for S. aureus (p=0.02). The 
median EASI score was 14.2 (IQR 9.9—19.2) and 9.1 (IQR 7.7—14.8), respectively. At T1, 
after the standardized two-week run-in treatment with triamcinolone, there was no differ-
ence in EASI score anymore between patients positive and negative for S. aureus (EASI 8.5 
(IQR 5.0—14.4) and 8.0 (IQR 4.8—12.0), respectively (p=0.55)). Interestingly, both the EASI 
score and the S. aureus density in nose and skin at T1 was significantly lower compared to 
T0 (Table 1 and Table S2). Looking into the abundance of the five most common spa-types 
per severity category, we did not find an overrepresentation of a certain spa-type (Figure 
S2). Because of the high number of spa-types with low prevalence and the fact that these 
numbers are accounted for by a few patients, this was not amenable for statistical testing. 
Between the patients with and without temporal variation in colonizing spa-type (nose 
and/or skin), the change in EASI score from T0 to T1 did not differ significantly (p=0.11, 
Figure S3).
discussion
Our study showed a heterogeneous S. aureus population between the AD patients, as 
seen in the general population. Spa-types t002, t091, t127, t571 and t189 were the most 
common and the remaining types were almost unique to one patient. A large proportion 
of the patients (79% at T0 and 78% at T1) had positive cultures in both the nose and skin 
and were colonized with only one spa-type. 80% (59/73) of the persistent nose carriers 
were colonized with the same spa-type compared to 79% (44/56) of the persistent skin 
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carriers. Lastly, we showed that disease severity was not affected by the spa-type present 
nor by a change in spa-type over time.
Our results are in line with previous publications describing a heterogeneous population 
structure of S. aureus in AD and the absence of a prevailing strain.14, 22, 23 Moreover, the 
most common spa-types found in our study population are also present in previously 
investigated AD populations and the general population, although the prevalence point 
estimates are not the same.14, 22-28 It could be argued that spa-typing does not have enough 
resolution to identify the genetic diversity between strains in AD. Compared to whole 
genome sequencing (WGS) techniques, that examines complete genomes, spa-typing is 
based on a single gene.29 However, WGS remains expensive to conduct in large series of 
cases and the spa-typing technique has been proven successful in settings requiring high 
levels of discrimination.29, 30
The nose is commonly described as the most important reservoir for S. aureus and several 
studies showed identical S. aureus strains in the nasal cavity and infected skin regions.7, 31, 32 
Moreover, nasal eradication with the application of an anti-staphylococcal agent leads 
to decolonization of other body sites and can prevent infection in surgical and dialysis 
patients, suggesting a causal relation between nasal carriage and infection.33, 34 Our results 
show that up to 79% of AD patients carried the same spa-type in the nose and on the skin, 
indicating clonal colonization within individual patients and a possible role for endogenous 
S. aureus transmission from nose to skin and/or vice versa. These data form an important 
lead for future intervention studies investigating the effect of nasal S. aureus eradication 
on skin colonization patterns and their role in current treatment guidelines
A large proportion of the patients was persistent S. aureus carrier in the nose (76%) and on 
the skin (58%). There is no general definition for persistent and intermittent skin carriers, 
nor consensus on how many cultures should be taken from a skin site to define these 
groups.7, 32 Studies in non-AD patients suggested that persistent carriers are colonized by 
a single strain in the nasal cavity over time and have a higher S. aureus load, with an 
increased risk of infection.7 Literature on this subject in AD patients is scarce and include 
low patient numbers, but seem to confirm these findings.13, 14, 17 Due to the absence of a 
general definition on carriership, the comparison between studies investigating S. aureus 
colonization patterns and temporal strain variation is difficult, as different sample fre-
quencies and definitions have been used. Our study, with a strict two-week follow-up and 
larger sample size, confirmed high rates of colonization by a single strain per individual in 
persistent carriers. We did not find a difference in disease severity between patients with 
and without temporal variation in colonizing S. aureus strain. However, more studies with 
larger populations should follow.
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We found a significantly higher EASI score at baseline in patients positive for S. aureus in 
comparison to S. aureus negative patients, which was not observed anymore after the 
two-week run-in period with triamcinolone (T1). Furthermore, a significantly lower EASI 
score and S. aureus load was seen at T1 as compared to T0. The discrepancies in these 
results could be explained by the standardized TCS treatment, which is known to suppress 
inflammation in AD skin. Our hypothesis is that, due to a suppression of inflammation, 
the skin can recover, making it less prone to S. aureus overgrowth. Thus, the use of TCS 
disturbs the correlation at this time point. This was also proposed in a previous study, 
showing a reduction in S. aureus load and a correlation with the disease severity after the 
use of TCS treatment.35
A major strength of this follow-up study is that all patients were sampled within the same 
interval of two weeks. Because treatment was similar in all patients, our results were not 
subject to differences in treatment regimens between participants. However, it is likely 
that the standardized use of corticosteroids affected the disease severity and S. aureus 
density.
This study has several limitations. First, due to a lack of a control group, we were not able 
to compare the presence of certain spa-types to a well characterized control population. 
For this reason, the spa-types present in our study population were compared to previ-
ous publications describing genetic populations in the general population and data from 
‘ridom SpaServer’.27 Second, as mentioned before, due to the spa-typing technique used 
we may have not detected changes in other genes that may be important in AD. Last, due 
to the high heterogeneity and low numbers per spa-type, statistical testing for differences 
between the genetic types was difficult. Larger studies using WGS will help to clarify the 
role of specific S. aureus genes rather than specific strains. Furthermore, the lack of as-
sociation of specific spa-types with disease severity encourages to further investigate the 
potential role of other virulence factors, beyond the spa-gene.
In conclusion, our results show that the colonizing S. aureus strains are not specific for AD 
and might rather be caused by host genetic and environmental factors. The majority of 
the AD patients is persistently colonized with identical S. aureus spa-types in the nose and 
skin. The results of this study underline the relevance of investigating the clinical benefit of 
anti-staphylococcal treatment in AD patients that are persistently colonized with S. aureus.
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Table s1. Frequency of spa-types in nose and skin





















sample missing 5 (1,7) 3 (1,9) 2 (1.5) -
t002 30 (10,3) 15 (9,6) 15 (11,3) 6,6 2,7(2) 5,0(3)
t005 4 (1,4) 2 (1.3) 2 (1.5) 0,7 2,8(4)
t008 13 (4,5) 8 (5,1) 5 (3,8) 5,9 5,1(4) 5,1(3)
t012 2 (0,7) 1 (0.6) 1 (0.8) 1,5 8,4(5) 6,2(4) 5,2(6) 2,2(3)
t015 4 (1,4) 4 (2,5) - 1,0 4,6(4) 0,1(3)
t019 1 (0,3) 1 (0.6) - 1,0
t021 11 (3,8) 6 (3,8) 5 (3,8) 1,1 4,0(4)
t024 1 (0,3) - 1 (0.8) 0,7
t026 5 (1,7) 3 (1,9) 2 (1.5) 0,5 0,1(3)
t050 1 (0,3) 1 (0.6) - 0,2
t065 3 (1,0) 2 (1.3) 1 (0.8) 0,5 4.9(5) 6,2(3)
t084 14 (4,8) 6 (3,8) 8 (6,0) 1,7 7.6(5) 7,7(6) 2,7(2) 5,4(3)
t091 23 (7,9) 14 (8,9) 9 (6,8) 1,0 5,2(4) 6,1(6) 1,0(3)
t100 3 (1,0) 2 (1.3) 1 (0.8) 0,0
t127 22 (7,6) 12 (7,6) 10 (7,5) 2,6 13,9(2) 2,1(3)
t1293 1 (0,3) 1 (0.6) - 0,0
t1307 1 (0,3) - 1 (0.8) 0,0
t1346 5 (1,7) 3 (1,9) 2 (1.5) 0,0
t1451 1 (0,3) 1 (0.6) - 0,2
t148 5 (1,7) 2 (1.3) 3 (2,3) 0,3 2,7(2)
t1504 2 (0,7) 2 (1.3) - 0,0
t160 7 (2,4) 3 (1,9) 4 (3,0) 0,3
t1601 1 (0,3) 1 (0.6) - 0,0
t164 4 (1,4) 2 (1.3) 2 (1.5) 0,2 11,1(2)
t189 18 (6,2) 7 (4,5) 11 (8,3) 0,6 19,4(2) 3,0(3)
t1994 4 (1,4) 2 (1.3) 2 (1.5) 0,0
t216 3 (1,0) 2 (1.3) 1 (0.8) 0,4
t2246 3 (1,0) 2 (1.3) 1 (0.8) 0
t230 6 (2,1) 2 (1.3) 4 (3,0) 0,4
t275 2 (0,7) 2 (1.3) - 0,1
t2973 3 (1,0) 1 (0.6) 2 (1.5) 0,0
t346 9 (3,1) 4 (2,5) 5 (3,8) 0,3 2,7(2) 1,0(3)
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t363 4 (1,4) 2 (1.3) 2 (1.5) 0,1
t369 1 (0,3) 1 (0.6) - 0,0
t398 4 (1,4) 2 (1.3) 2 (1.5) 0,1
t445 2 (0,7) 2 (1.3) - 0,0
t458 2 (0,7) - 2 (1.5) 0,1
t491 1 (0,3) 1 (0.6) - 0,1 1,0(3)
t5078 1 (0,3) 1 (0.6) - 0,0
t559 2 (0,7) 1 (0.6) 1 (0.8) 0,0
t571 19 (6,6) 10 (6,4) 9 (6,8) 0,4
t6587 1 (0,3) 1 (0.6) - 0,0
t686 4 (1,4) 2 (1.3) 2 (1.5) 0,0
t693 2 (0,7) 1 (0.6) 1 (0.8) 0,1
t774 1 (0,3) 1 (0.6) - 0,1 1,0(3)
t803 5 (1,7) 2 (1.3) 3 (2,3) 0,1
t837 7 (2,4) 4 (2,5 3 (2,3) 0,0
t854 2 (0,7) 2 (1.3) - 0,0
t975 1 (0,3) 1 (0.6) - 0,0
t9252 3 (1,0) 2 (1.3) 1 (0.8) -
t9253 4 (1,4) 2 (1.3) 2 (1.5) -
t9254 1 (0,3) - 1 (0.8) -
t19255 4 (1,4) 2 (1.3) 2 (1.5) -
unknown1 1 (0,3) - 1 (0.8) -
unknown2 1 (0,3) - 1 (0.8) -
Total 290 (100,0) 157 (100,0) 133 (100,0) -
Column 2, 3 and 4 represent data from this present study and are collected during both time points. The 
marked cells represent the five most common spa-types. Column 5 represent the world’s prevalence of spa-
types as registered by the ridom spa-server. Column 6 represents the prevalence of spa-types in the nose as 
described by previous publications on the presence in the general European populations. Column 7 repre-




Table s2. S. aureus load in nose and skin at both time points
T0 T1 P-valuea
nose n(%) P<0.03
Load 1 19 (24.4) 21 (27.3)  
Load 2 31 (39.7) 33 (42.9)  
Load 3 26 (33.3) 18 (23.4)  
Load 4 2 (2.6) 5 (6.5)  
Total 78 77  
skin n(%) P=0.04
Load 1 22 (31.4) 24 (38.7)  
Load 2 24 (34.3) 30 (48.4)  
Load 3 16 (22.9) 7 (11.3)  
Load 4 8 (11.4) 1 (1.6)  
Total 70 62  
Results on S. aureus load were determined using bacterial semi-quantitative cultures and reported on a cat-
egorical scale ranging from 0 (negative) to 4 (strongly positive). Abbreviations: n, number; T0, baseline. T1, 
two weeks after baseline. aStatistical testing was performed using a Chi-square test.
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Disease severity (EASI score)a
Time point T0


















Disease severity (EASI score)a
Time point T1
t002 t091 t127 t189 t571
Figure s2. The abundance of the five most common spa-types per severity score
The five most common spa-types found in nose and skin in relation to the EASI score. A. At baseline (T0) in 
patients positive for S. aureus. B. Two weeks after baseline (T1) in patients positive for S. aureus. There was no 
overrepresentation of a specific spa-type per severity category at T0 and T1. Abbreviations: EASI, Eczema Area 
and Severity Index; T0, baseline. T1, two weeks after baseline; n, number. aDisease severity represented by 
EASI categories. Almost clear = EASI score 0.1– 1.0; Mild = EASI score 1.1–7.0; Moderate = EASI score 7.1–21.0; 




Staphylococcus aureus genotypes in atopic dermati ti s






























Figure s3. Disease severity separated for pati ents with and without temporal variati on in spa-type
The pati ent group carrying an identi cal spa-type (in nose and skin) at both ti me points had a reducti on in EASI 
score from a median of 12.7 (IQR 10.7-19.1) to 8.8 (IQR 5.0-14.7). Pati ents with a temporal variati on in spa-
type (nose and/or skin) had a median EASI score of 18.2 (IQR 14.6-22.0) and 7.8 (IQR 4.8-14.9) at T0 and T1, 
respecti vely. The change in EASI score between both groups was not stati sti cally signifi cant. Abbreviati ons: 





 1. GmbH R. [updated December 2005. Available from: https://www.spaserver.ridom.de/.
 2. Kim DW, Park JY, Park KD, Kim TH, Lee WJ, Lee SJ, et al. Are there predominant strains and toxins of 
Staphylococcus aureus in atopic dermatitis patients? Genotypic characterization and toxin deter-
mination of S. aureus isolated in adolescent and adult patients with atopic dermatitis. J Dermatol. 
2009;36(2):75-81.
 3. Yeung M, Balma-Mena A, Shear N, Simor A, Pope E, Walsh S, et al. Identification of major clonal 
complexes and toxin producing strains among Staphylococcus aureus associated with atopic der-
matitis. Microbes Infect. 2011;13(2):189-97.
 4. Holtfreter S, Grumann D, Balau V, Barwich A, Kolata J, Goehler A, et al. Molecular Epidemiology of 
Staphylococcus aureus in the General Population in Northeast Germany: Results of the Study of 
Health in Pomerania (SHIP-TREND-0). J Clin Microbiol. 2016;54(11):2774-85.
 5. Sangvik M, Olsen RS, Olsen K, Simonsen GS, Furberg AS, Sollid JU. Age- and gender-associated 
Staphylococcus aureus spa types found among nasal carriers in a general population: the Tromso 
Staph and Skin Study. J Clin Microbiol. 2011;49(12):4213-8.
 6. Becker K, Schaumburg F, Fegeler C, Friedrich AW, Kock R, Prevalence of Multiresistant Microorgan-





The skin and nose microbiome and its 













Increased Th22 cell numbers in a general 
pediatric population with filaggrin 












*These authors contributed equally to this work





Mutations in the filaggrin gene (FLG) affect epidermal barrier function and increase the 
risk of atopic dermatitis (AD). We hypothesized that FLG mutations affect immune cell 
composition in a general pediatric population. Therefore, we investigated whether school-
aged children with and without FLG mutations have differences in in T- and B-cell subsets.
methods
This study was embedded in a population-based prospective cohort study, the Genera-
tion R Study, and included 523 children of European genetic ancestry aged 10 years. The 
most common FLG mutations in the European population (R501X, S1085CfsX36, R2447X 
and S3247X) were genotyped. Additionally, 11-color flow cytometry was performed on 
peripheral blood samples to determine helper T (Th), regulatory T (Treg) and CD27+ and 
CD27- memory B cells. Subgroup analyses were performed in 358 non-AD and 102 AD 
cases, assessed by parental questionnaires.
results
FLG mutations were observed in 8.4% of the total population and in 15.7% of the AD cases. 
Children with any FLG mutation had higher Th22 cell numbers compared to FLG wild-type 
children in the general and non-AD population. Children with and without FLG mutations 
had no difference in Th1, Th2, Th17, Treg or memory B cell numbers. Furthermore, in 
children with AD, FLG mutation carriership was not associated with differences in T- and 
B-cell subsets.
conclusions
School-aged children of a general population with FLG mutations have higher Th22 cell 
numbers, which reflects the immunological response to the skin barrier dysfunction. 
FLG mutations did not otherwise affect the composition of the adaptive immunity in this 
general pediatric population.
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inTroducTion
Filaggrin is a filament-associated protein that is encoded by the filaggrin gene (FLG) and is 
an important contributor to the preservation of the skin barrier.1, 2 Approximately 10% of 
the European population is a heterozygote carrier of a disrupting mutation in FLG.3 Both 
complete loss-of-function and reduced functional activity of filaggrin lead to destruction of 
the stratum corneum (SC) and consequently skin barrier dysfunction.1, 4 This barrier dysfunc-
tion due to FLG mutations is presumed to be caused by lower numbers of tight junctions, 
reduced density of the protein corneodesmosin, and impaired maturation and excretion of 
lamellar bodies in the epidermis which are important in maintaining cell-to-cell integrity.2
Failure in barrier function through mutations in FLG results in increased skin permeability 
for percutaneous transfer of exogenous particles including allergens and pollutants.1, 2, 4 Ac-
cordingly, FLG mutations are the strongest genetic risk factor for atopic dermatitis (AD).1, 3, 5 
A previous meta-analysis showed that FLG haploinsufficiency results in an odds ratio (OR) 
of 3.12 for the incidence of AD.6 In addition, FLG mutations are associated with a form 
of AD that starts in early infancy and persists into adulthood, a higher incidence of skin 
infections and a higher likelihood of having asthma, inhalant or food allergies.2, 7-9
The increased permeability of the skin as a result of FLG mutations is thought to affect 
immune responses and maturation of adaptive immune cells. Filaggrin is also expressed 
in the thymus, the primary lymphoid organ in which T cells are formed.10 Hence, FLG 
mutations potentially affect the peripheral immune cell compartment through effects in 
skin and thymus. Previous studies observed higher γδT17 and T helper (Th) 17 in filaggrin-
deficient flaky tail (ft/ft) mice.10, 11 In addition, a case study reported higher numbers of 
circulating thymus-emigrated regulatory T (Treg) cells and Th2 in 6 AD patients with a 
heterozygote FLG mutation.12 Another study, including 2 heterozygous, 2 homozygous and 
1 compound heterozygous AD patient, showed increased Th17 cells in the FLG mutation 
group.11 On the other hand, literature on the role of B cell dysregulation in AD is scarce and 
conflicting.13-16 It can be hypothesized that mutations in FLG can affect B-cell numbers due 
to skewing of the Th-cell populations.
We hypothesized that FLG mutations affect T- and B-cell maturation in children through 
effects on the skin and thymus. Until now, no studies on this association have been per-
formed in the general pediatric population and only case studies have been performed in 
AD patients.11, 12 By examining the effect of FLG mutations on the adaptive immune cells, 
we will gain more insights into the role of FLG in the immune maturation and development 
of AD. Therefore, we here studied the associations between common FLG mutations in the 
European population and immune cell numbers, as determined using with 11-color flow 
Chapter 3.2
76




This study was embedded within the Generation R Study, a prospective birth cohort study 
conducted in Rotterdam, the Netherlands. The Medical Ethical Committee of the Erasmus 
MC, University Medical Center Rotterdam approved the study (MEC-2012-165).17 Written 
informed consent was obtained from parents or legal representatives of all children. We 
included all children of European genetic ancestry18 with information on FLG mutation sta-
tus (homozygous, compound heterozygous, heterozygous or wild type) and information on 
at least one of the immune cell outcomes. This resulted in a total number of 523 children 
(Figure 1). AD was defined as physician-diagnosed eczema from parental questionnaires 
obtained at the child’s age of 10 years (‘Was your child ever diagnosed by a physician with 
atopic dermatitis’, ‘yes; no’). This information was available for 470 children, including 102 
subjects with AD.16
FLG genotype
DNA samples obtained from umbilical cord blood were genotyped by modified Taqman 
allelic discrimination assays for common European mutations in FLG (R501X (rs61816761), 
S1085CfsX36 (rs41370446), R2447X (rs138726443), and S3247X (rs150597413)) with 
the use of primers as described previously.19, 20 The distribution of the FLG mutations 
was as follows: 4.2% had R501X (rs61816761), 1.1% had S1085CfsX36 (rs41370446), 
3.5% had R2447X (rs138726443), and 0.0% had S3247X (rs150597413). Because S3247X 
(rs150597413) was not present within our study population, this mutation was not in-
cluded in the analyses. Children were classified as having a FLG mutation if they were 
homozygous, compound heterozygous or heterozygous for any of the 3 mutations that 
were present in our study population. Children without any of the mutations were classi-
fied as wild type.
immune cell numbers
Peripheral blood samples from children were obtained at the age of 10 years.16 The analy-
ses were performed on fresh blood cells within 24 hours of sampling. Absolute counts 
of CD3+ T cells and CD19+ B cells per μLblood were determined with diagnostic lyse-
no-wash protocol and detailed immunophenotyping was performed with 11-color flow 
cytometry (LSR Fortessa, BD Biosciences). We determined naïve T cells (CD45RO-CCR7+), 
effector memory RO-positive T cells (TemRO; CD45RO+CCR7-) and effector memory RA-
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positive T cells (TemRA; CD45RO-CCR7-) within CD4+ and CD8+ lineages.16, 21, 22 Within Treg 
cells, the differentiation in naive (CD45RA+) and memory (CD45RA-) was determined.16 
Finally, the following Th cell subsets (CD4+CD45RA-) were determined after exclusion 
of Treg cells on the basis of chemokine receptor profiles as defined previously:16, 23-27 
Th1 (CCR6−CXCR3+CCR4−), Th2 (CCR6−CXCR3−CCR4+), Th17 (CCR6+CXCR3−CCR4+CCR10-), 
Th17.1(CCR6+CXCR3+CCR4–) and Th22 (CCR6+CXCR3–CCR4+CCR10+). In addition CD27+ and 
CD27- IgG+, IgA+, IgE+ CD19+CD38dimIgD- memory B cell subsets were defined.16 Gating 
strategies for Th cell determination are presented in Figure S3.
statistical analysis
First, characteristics of the study population were determined, stratified for FLG mutation 
status and AD diagnosis. P-values for determining differences between the categorical 
variables of both groups were calculated with chi-squared tests. Next, median cell num-
bers with interquartile range (IQR) were determined. Differences in cell numbers between 
Figure 1. Flow chart of participants included in the study
Abbreviations: Th, helper T cell; Treg, regulatory T cell.; Tcm, central memory T lymphocytes; TemRA, effector 
memory RA-positive T lymphocytes; TemRO, effector memory RO-positive T lymphocytes
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children with and without FLG mutations were assessed with the non-parametric Mann-
Whitney U test. Subgroup analyses on the associations of FLG genotype with immune 
cell numbers were performed within non-AD and AD children. The possibility of effect 
modification by AD diagnosis was tested by performing linear regression analysis between 
immune cell numbers and FLG mutation status with the addition of an interaction term 
between FLG mutation status and AD diagnosis. To assure a normal distribution of the 
outcome in the linear regression analysis, a natural-log transformation for the immune cell 
outcomes was used. No adjustment for multiple testing was performed because of strong 
correlation between the immune cells studied. Statistical analyses were performed with 
SPSS version 21.0 (IBM Corp.) and R version 3.6.1 (R Foundation for Statistical Computing).
resulTs
study population
Characteristics of the study population are presented in Table 1. Within the total group 
of 523 children with European ancestry, FLG mutations were detected in 44 (8.4%) chil-
dren, including 3 biallelic mutations (2 compound heterozygous and 1 homozygous). The 
proportion of patients with AD was lower in the wild-type group compared to the group 
with FLG mutations (20% versus 42%; p<0.01). Within the non-AD population, 6.1% of 
the children had a FLG mutation, including one compound heterozygous. Within the AD 
population, 15.7% of the children had a FLG mutation, including one homozygous and one 
compound heterozygous.
Higher Th22 cell counts in children of the general population with FLG mutations
Children of the general population with a FLG mutation had higher Th22 cell numbers 
compared to children of the wild-type population (Figure 2A, Table S1). The median cell 
number within the FLG mutation group was 5.60/μL (IQR 4.04;8.94) and 4.5/μL (IQR 
2.5;7.4, p=0.03) within the wild-type group. To determine if this association between 
Th22 and FLG was different between children with and without AD, we performed a 
linear regression analysis with the following interaction term: FLG mutation status*AD. 
This interaction term was non-significant (p=0.13) and therefore effect modification by AD 
in this association is not likely. However, when the analyses were stratified, the associa-
tion between FLG and Th22 was slightly stronger in the non-AD group with a median cell 
number of 6.8/μL (IQR 4.9;11.4) in non-AD children with FLG mutations compared to 4.5/
μL (IQR 2.4;7.5, p=0.006) in non-AD children without FLG mutations (Table S2). In contrast, 
when studying the differences in absolute Th22 cell numbers between children with and 
without FLG mutations in the AD population, no significant differences were observed 
(median  5.0/μL (IQR 3.6;6.4) and 4.6/μL (IQR 2.9;7.4) respectively (p=0.64, Figure S1a)).
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Figure 2. Absolute numbers of blood T cell subsets stratified by FLG mutation status
(A)The median (IQR) cell count per μLblood for Th and Treg cell numbers stratified for FLG mutation status. 
(B) The median (IQR) cell count per μL blood for CD4+ and CD8+ effector memory T cell numbers stratified for 
FLG mutation status. Abbreviations: IQR, interquartile range; Tcm, central memory T lymphocytes; TemRA, 
effector memory RA-positive T lymphocytes; TemRO, effector memory RO-positive T lymphocytes; Th, helper 
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no associations between Th1, Th2, Th17 and Treg and FLG mutations
No differences in median cell numbers between FLG mutation and wild-type group were 
observed for Th1, Th2, Th17 and Treg (Figure 2a, Table S1). This was similar in the sub-
group analyses that were stratified for AD diagnosis (Figure S1a, Table S2). No differences 
in median cell numbers between the FLG mutation and the wild-type group were observed 
for the effector memory CD4+ and CD8+ T cell subsets: naive, Tcm, TemRA, TemRO (Figure 
2b, Figure S1b).
no associations between memory b cells and FLG mutations
No differences in median cell numbers between the FLG mutation and the wild-type group 
were observed for total B cells and naive mature B cells (Table S1). In addition, no associa-
tions between FLG mutations and the following CD27+ and CD27- memory B cell subsets 
were observed: IgA+, IgE+, IgG+, IgM+ (Figure 3). Similarly, no changes were observed in the 



















































Figure 3. Absolute numbers of blood memory B cell subsets stratified by FLG mutation status
The median (IQR) cell count per μL blood for B memory cell numbers stratified for FLG mutation status are 





In this population-based study among children of European genetic ancestry, we observed 
a prevalence of 8.4% for FLG mutations. In addition, we demonstrated that children with 
FLG mutations had higher Th22 cell numbers than children without FLG mutations. In 
contrast, the Th1, Th2, Th17, Treg and memory B cell numbers were comparable between 
children with and without FLG mutations. In addition, among children with AD, those with 
or without FLG mutations had no differences in B- or T-cell subsets.
comparison with literature and interpretation
All previous studies on FLG mutations and immune cell numbers have been performed 
within mice models or smaller numbers of AD patients.10-12, 28 This is the first study that 
provides insight into the role of FLG mutations on immune cell numbers in school-aged 
children of a general population. The setting of this study within a population-based pedi-
atric cohort study is therefore unique to study the association between FLG and immune 
cell numbers.
We observed higher Th22 cell numbers in children with FLG mutations in the general 
population, with a slightly higher median Th22 cell number in non-AD children with a 
mutation in FLG. No previous studies that assess the association between FLG mutations 
and Th22 have been performed within a general population. Interestingly, in contrast to 
our findings, several studies have observed increased Th22 cell numbers in the skin and 
circulation of patients with AD.29, 30 Within AD patients, the role of Th22 is still not fully 
elucidated. Current literature suggests both protective and pro-inflammatory roles for 
Th22 by the production of IL-22.31 IL-22 contributes to skin integrity and is known for its 
role in the defense against different pathogens in the skin by the production of antimi-
crobial proteins.32, 33 However, the combined secretion of IL- 22 and TNF- α is thought to 
have an pro-inflammatory effect as observed in AD.31 Possible explanations for the higher 
number of Th22 cell numbers in children without AD but with FLG mutations could be the 
following. First, the increase in Th22 could represent some level of inflammation due to 
FLG mutations without apparent clinical symptoms. Second, hypothetically, the increase 
in Th22 could contribute to skin homeostasis in children without AD to prevent further 
inflammatory processes leading to AD. However, further studies are needed to elaborate 
on the Th22 cell function in children with and without AD.
In contrast to previous studies investigating the effect of the FLG mutation status, we 
did not observe differences in Th2, Th17 and Treg cell numbers between children with 
and without FLG mutations, both in the total study population and in the subgroup of 
patients with AD.10-12, 28 The discrepancies between previous studies and this study could 
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be explained by differences in investigated populations and species. Previous mice studies 
and skin equivalents studied the effect of complete absence of filaggrin, compared to the 
filaggrin haploinsufficiency in our study population which leads to 50% reduction in filag-
grin expression.2, 10, 28 In addition, these studies could represent a different immunological 
setting than is present in human skin. 28 It is also expected that previous results on immune 
cell numbers in AD populations are affected by disease severity. Namely, the presence of 
different immune cells is dependent on disease state, including disease flare and chronic 
AD.29, 30 In turn, immune cells in active AD skin can induce downregulation of filaggrin pro-
tein expression in the skin independent of FLG mutations, subsequently affecting immune 
cell composition.20 Although we do not have information on disease severity in our AD 
population, this study included a population-based, relatively healthy cohort in which we 
expect most children to have mild AD. Therefore, we suspect that alterations in immune 
cell numbers is probably not only dependent on FLG mutation genotype, but also on AD 
severity and epigenetic and environmental factors.
In addition, we did not observe differences in memory B cell numbers between children 
with and without FLG mutations. This is in line with our previous study in which we did not 
observe any association between B cells and AD.16 No previous studies have investigated B 
cell subsets in relation to FLG mutations.
Finally, within our study, we studied the associations between FLG mutations and the 
adaptive immunity. It can be speculated that FLG mutations cause alterations in the in-
nate immunity such as eosinophilic granulocytes and ILC2 cell numbers. Future studies 
are needed to determine if FLG mutations are associated with altered innate immunity 
cell numbers.
Methodological considerations
A major strength is that this study investigated the association between FLG genotype 
and a large panel of T- and B-cells in the general population for the first time. We had 
detailed and extensive information on immune cell numbers from 11-color flow cytom-
etry and obtained objective information on genetic ancestry. However, the following four 
limitations need to be addressed. First, we used chemokine receptor profiles which are 
surrogate markers of Th cells. Due to the large scale of our study and the need to process 
fresh blood within 24 hours, in vitro activation and cytokine staining were not feasible. 
Importantly, multiple studies have shown that the use of surface chemokine receptors 
is a robust approach to define Th subsets with the corresponding cytokine profiles.23, 24 
Second, the AD population for the subgroup analyses was relatively small which could 
have limited the power in the statistical analyses. Nevertheless, in comparison to previous 
studies, only including a maximum of 6 AD patients with FLG mutations, this is the largest 
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study on FLG mutations in both the general population and in AD patients. Third, our AD 
population was defined by ever having physician diagnosed AD before or at the age of 10 
years and no information on current disease activity was available. Therefore, it is likely 
that a part of the children has outgrown AD at the age of 10 and this might have affected 
their immunophenotype. Fourth, as mentioned previously, our study included the four 
most common FLG mutations in the European population. To prevent misclassification, 
we selected children with genetic European ancestry for the current study. Although the 
choice for including the most common FLG mutations in European populations is in line 
with previous studies,11, 12 other less frequent FLG mutations could exist in low numbers 
since up to 113 FLG mutations resulting in premature protein termination have been 
described.34 A recent study including patients with AD and Ichthyosis Vulgaris (IV), showed 
that screening the entire encoding region of FLG for mutations led to an improvement 
of the diagnostic yield.34 As this is the first study in a general cohort addressing the as-
sociation between FLG mutation and immune cell numbers, future studies are needed to 
validate our results.
In conclusion, school-aged children of a general population with FLG mutations have 
higher Th22 cell numbers, which might reflect the skin barrier dysfunction that is caused 
by decreased filaggrin expression in the epidermis. In our study population, FLG muta-
tions do not otherwise affect the composition of the adaptive immune cells in a general 
pediatric population, nor in the children with AD.
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suPPleMenTAry MATeriAl
Table s1. The median (IQR) cell counts per μL blood for T- and B-cells subsets stratified by FLG mutation status
Total study population (n=523)
Wild-type population (n=479) FLG mutation carriers (n=44) P-valuea
Th1 32 (20.0-48.5) 30.1 (20.2-39.6) 0.31
Th2 53.8 (38.3-77.1) 51.7 (38.3-71.0) 0.99
Th17 30.5 (20.6-43.8) 35.7 (19.7-49.2) 0.13
Th22 4.5 (2.5-7.4) 5.6 (4.04-8.9) 0.03
Treg 77.5 (58.6-98.6) 77.8 (67.6-102.0) 0.48
Treg naive 45.4 (31.2-63.2) 46.4 (36.4-63.5) 0.25
Treg memory 29.6 (23.0-39.6) 29.3 (24.0-34.9) 0.74
Total b cells 478.5 (370.0-632.0) 493.0 (389.5-575.8) 0.69
b naive 303.1 (228.9-416.6) 323.2 (245.6-366.9) 0.90
igM only 3.5 (2.2-5.27) 2.7 (1.6-5.1) 0.06
cd27-igG+ 4.4 (2.5-7.3) 3.7 (2.1-5.6) 0.14
cd27+igG+ 15.8 (10.0-23.8) 14.7 (10.2-19.5) 0.29
cd27-ige+ 0.1 (0.1-0.3) 0.1 (0.1-0.2) 0.69
cd27+ige+ 0.3 (0.2-0.5) 0.3 (0.1-0.4) 0.33
cd27-igA+ 2.1 (1.3-3.1) 1.7 (1.3-2.8) 0.26
cd27+igA+ 11.4 (8.2-15.8) 10.8 (7.3-14.7) 0.30
cD4+ total 1076.8 (865.2-1291.9) 1098.8 (913.2-1278.1) 0.76
cD4+ naive 677.8 (511.3-882.0) 711.8 (549.2-815.8) 0.49
cD4+ Tcm 167.5 (112.8-240.0) 164.8 (108.1-221.5) 0.41
cD4+ TemrA 17.8 (8.3-38.8) 11.4 (7.3-37.9) 0.39
cD4+ Temro 136.8 (92.4-200.0) 128.6 (94.6-208.4) 0.75
cD8+ total 612.3 (489.4-755.5) 630.5 (471.1-780.6) 0.96
cD8+ naive 322.1 (247.9-441.6) 317.9 (268.3-400.8) 0.94
cD8+ Tcm 23.6 (11.8-39.9) 28.1 (14.0-46.2) 0.37
cD8+ TemrA 86.4 (52.7-137.8) 74.5 (42.8-140.6) 0.45
cD8+ Temro 82.3 (52.9-115.0) 83.0 (56.3-123.9) 0.45
Abbreviations: Ig, immunoglobulin; IQR, interquartile range; Tcm, central memory T lymphocytes; TemRA, ef-
fector memory RA-positive T lymphocytes; TemRO, effector memory RO-positive T lymphocytes; Th, helper T 
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cD4+ T cells 502 339 101
CD4+ T naive 511 347 102
CD4+ TCM 511 347 102
CD4+ TEMRO 511 347 102
CD4+ TEMRA 511 347 102
Th1 cells 499 336 101
Th2 cells 498 335 101
Th17 cells 496 335 100
Th22 cells 495 334 100
Treg cells 493 334 98
Treg naïve 492 334 98
Treg memory 492 334 98
cD8+ T cells 499 337 101
CD8+ T naive 509 345 102
CD8+ TCM 509 345 102
CD8+ TEMRO 509 345 102
CD8+ TEMRA 509 345 102
Total b cells 522 357 102
B naive 512 347 102
IgM only 511 346 102
CD27-IgG+ 511 346 102
CD27+IgG+ 511 346 102
CD27-IgE+ 511 346 102
CD27+IgE+ 511 346 102
CD27-IgA+ 511 346 102
























































































Figure s1. Absolute numbers of blood T cell subsets stratified by FLG mutation status in children with atopic 
dermatitis
(A-B) The median (IQR) Th, Treg, CD4+ and CD8+ Tem cell count per μL blood stratified for FLG mutation status. 























































Figure s2. Absolute numbers of blood memory B cell subsets stratified by FLG mutation status in children with 
atopic dermatitis.
The median (IQR) cell count per μL blood for B memory cell numbers stratified for FLG mutation status. Ab-
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Natural moisturizing factor as a biomarker 
for filaggrin mutation status in a multi-













The influence of treatment in alpine 
and moderate maritime climate on the 
composition of the skin microbiome in 














The skin microbiome, characterized by an overgrowth of Staphylococcus (S.) aureus, plays 
an important role in the pathogenesis of atopic dermatitis (AD). Multidisciplinary treat-
ment in alpine climate is known for its positive effect on disease severity in children with 
AD and can result in a different immune response compared with moderate maritime 
climate. However, the effect on the composition of the skin microbiome in AD is unknown.
objective
To determine the effect of treatment in alpine climate and moderate maritime climate 
on the microbiome for lesional and nonlesional skin in children with difficult to treat AD.
methods
This study is part of the DAVOS trial (ISRCTN88136485), a pragmatic randomized con-
trolled trial in which 84 children with difficult to treat AD were randomized to a six-week 
personalized integrative multidisciplinary treatment in either alpine climate (intervention) 
or moderate maritime climate (control). Before and directly after treatment, swabs were 
collected from the lesional and nonlesional skin and analyzed using 16S rRNA sequencing. 
Additional quantitative (q)PCR for S. aureus and S. epidermidis was performed.
results
Alpine climate treatment led to a significant change in the microbiome on lesional skin, 
whereas no significant change was found after moderate maritime climate. On both le-
sional and nonlesional skin, we observed a significant increase in Shannon diversity and 
a significant decrease in both Staphylococcus genus abundance and S. aureus load after 
alpine climate treatment. The decrease in S. aureus was significantly larger on lesional skin 
following alpine climate treatment compared with moderate maritime climate treatment. 
S. epidermidis load was stable over time.
conclusion
Alpine climate treatment leads to significant changes in the composition of the skin micro-
biome in children with AD, mainly caused by a reduction in the Staphylococcus genus. This 
study shows new perspectives in the potential mode of action for therapies in AD.
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Alpine climate treatment and the microbiome
inTroducTion
Atopic dermatitis (AD) is a chronic, relapsing skin disease with a prevalence of 10-20% 
in West-European children.1 AD is characterized by immunological changes, skin barrier 
dysfunction and changes in the microbial composition on the skin, influenced by genetics 
and environmental factors. While the skin barrier and the immune system were the most 
important factors in AD etiology, the role of the skin microbiome gained more attention 
due to development of new molecular methods.2, 3 The skin microbiome is in constant 
interaction with the skin barrier and immune system, reinforcing the process of inflam-
mation.4-6 The skin in AD is characterized by an overgrowth of Staphylococcus (S.) aureus 
and analysis of the skin microbiome in different disease states of AD showed a correlation 
between the abundance of S. aureus and disease severity, with a higher load during dis-
ease flares.7 Also, a reduced diversity of other bacteria on the skin was found.6-8
AD treatment involves epidermal barrier repair using emollients, anti-inflammatory 
therapy using corticosteroids and trigger avoidance. In cases of severe (or infected) AD, 
systemic treatment and antimicrobial therapy is used.9, 10 Alpine climate therapy has been 
used in patients with asthma and AD for decades. This climate is characterized by lower 
exposure to allergens and pollution and an increased ultraviolet radiation (UV-R).11-13 The 
rationale of alpine climate therapy is mainly based on trigger avoidance and dampening 
the immune response. A recent study exploring the underlying immunological effects of 
alpine climate therapy found a significant reduction in blood eosinophils and an increase 
in circulating memory B cells, CD8+ T cells and T helper (Th)2 cells which reflected a reduc-
tion in disease severity.14-16
It is known that climate factors can influence the skin microbiome. A study performed 
in healthy individuals within different humidity and temperature conditions showed an 
effect on the quantities of bacteria on the skin.17 Furthermore, UV-R can modulate the 
skin microbiome by causing direct microbial DNA damage and by affecting the immune 
system.18-21
Evaluation of alpine climate treatment has mainly focused on the immune system. The 
effect of alpine climate on the skin microbiome is still unclear. Identification of the skin 
microbiome and factors influencing the microbial composition might help in developing 
treatment strategies that improve disease severity by targeting the microbiome. There-
fore, the aim of this study was to assess the effect of alpine climate treatment on the skin 
microbiome in children with difficult to treat AD in a randomized controlled trial (RCT), 






This study is incorporated in the DAVOS-trial, a pragmatic RCT including children with dif-
ficult to treat AD. The trial is registered at Current Controlled Trials (ISRCTN88136485). The 
detailed study protocol and primary outcomes have been published previously.22, 23 Briefly, 
Dutch children and adolescents were randomized to a six-week personalized integrative 
multidisciplinary (PIM) treatment in either a clinic in the Swiss alps at 1560 meters (inter-
vention, alpine climate group) or an outpatient treatment program in the Netherlands in 
moderate maritime climate (control, moderate maritime climate group). Patients were 
assessed before the start of treatment (time point T0) and within 72 hours after the end 
of the six-week treatment (time point T1). All study assessments were performed in the 
Netherlands. Study procedures were reviewed and approved by the Medical Ethics Com-
mittee of the University Medical Center Utrecht, the Netherlands (reference 09-192/K). 
This study involves secondary outcomes of this trial.
Participants
Dutch children between 8 and 18 years old with difficult to treat AD were eligible for 
participation in the study. We defined difficult to treat AD as the need for at least a class 
3 topical corticosteroid and not being able to step down, or current use of systemic im-
munosuppressive treatment, or repeated treatment with potent topical corticosteroids 
or systemic immunosuppressive treatment, or a history of use of systemic treatment, 
or a significant impact of AD on the child’s or the families quality of life, or seemingly 
unresponsive to conventional therapy according to current guidelines.23 All patients and 
if needed, their parents provided written informed consent. Demographic data were 
extracted from questionnaires and the electronic patient file. Microbiome samples were 
obtained prior to and after the end of the six-week treatment in the Wilhelmina Children’s 
Hospital Utrecht, the Netherlands.
Microbial samples
Microbial samples were collected from the lesional and nonlesional skin. Samples taken 
from the lesional skin were preferably taken from the antecubital fold or the popliteal fold. 
Nonlesional skin samples were taken from the volar arm if possible. Sterile cotton swabs 
soaked in NaCl 0.9% were used to collect all samples. Skin samples were collected by 
rubbing the skin for 30 seconds. All samples were stored at -80ᵒC until further processing.
dnA isolation and qPcr
For DNA isolation phenol extraction and magnetic beads were used (Agowa mag Mini DNA 
isolation kit; LCG). First, 150 µL from the sample was added to 350 µL lysis buffer, 500 µL 
117
Alpine climate treatment and the microbiome
Phenol (Tris pH 8) and 500 µL 0,1 mm zirconium beads. This mixture was mechanically 
disrupted with a beadbeater (Biospec products, Bartelsville) twice for 2 minutes, followed 
by centrifuging for 10 minutes at 1690 RCF to separate the aqueous and phenolic phases. 
The aqueous phase was purified using AGOWA mag Mini DNA isolation kit. The bacterial 
DNA concentration measured after DNA extraction was performed using universal 16-S 
qPCR (16S-uni-I-F (5’- CGA AAG CGT GGG GAG CAA A -3’), 16S-uni-I-R (5’- GTT CGT ACT CCC 
CAG GCG G -3’), 16S-uni-I MGB Taqman® probe (5’- ATT AGA TAC CCT GGT AGT CCA  -3’) 
with FAM™ label).  S. aureus and S. epidermidis load were quantified using multiplex qPCR 
with the following combination of primers and probes: 16S-S.aur-F1 (5’-GCG AAG AAC CTT 
ACC AAA TCT TG-3’), 16S-S.aur-R1 (5’-TGC ACC ACC TGT CAC TTT GTC-3’), 16S-S.aur MGB 
Taqman® probe (5’-CAT CCT TTG ACA ACT CT-3’) with NED™ label. 16S-S.epi-R1 (CAT GCA 
CCA CCT GTC ACT CTG T) and the 16S-S.epi MGB Taqman probe (CCT CTG ACC CCT CTA G) 
with VIC label. 40 cycli of qPCR were performed. The DNA concentration was reported as 
log10 transformed, femtogram per microliter (fg/ul) in this paper. Detailed information 
about the DNA concentrations before log transformation are noted in Table S1.
16s rrnA sequencing and taxonomic classification
Microbiome analysis was performed with massively sequencing of the 16S rRNA gene 
using V4 hypervariable region on the Illumina MiSeq sequencer (Illumina, San Diego, CA). 
Barcoded DNA fragments spanning the V4 hypervariable region were amplified with a 
standardizing level of template DNA (1 ng). This was used to prevent over-amplification. 
Amplicons, generated using adapted primers F515 and R806 (using 30 PCR cycles), were 
bidirectionally sequenced using the MiSeq system.24 Samples containing insufficient 
amounts of DNA did not result in usable sequence data and were therefore omitted. 
Pre-processing and classification of sequences was performed using the Mothur V.1.31.1 
software platform. To assign taxonomic names, the Ribosomal Database Project (RDP) 
Classifier was used.25 Technical performance was checked by using standardized mock 
communities. Negative control samples of the lysis buffer did not show signs of contami-
nation. A genus table with raw read counts was generated for downstream analysis.
statistical analysis
Our statistical analyses were performed in patients with available data at both time points 
per outcome. Shannon diversity index was calculated at genus level on non-subsampled 
unfiltered data. For further analysis of the microbiome we used non-subsampled genus 
tables and excluded genera with a relative abundance lower than 0.0001. Prior to ordina-
tion analysis, the filtered genus tables were square root transformed with subsequent 
application of Wisconsin double standardization. To visualize bacterial community 
compositions, Bray-Curtis distance based multidimensional scaling (MDS) was used. Per-
mutational multivariable analysis of variance (PERMANOVA) was used to determine 
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significant changes in microbiome. To assess if the change in microbiome was significantly 
different between both treatment groups we used the covariates ‘time point’ (T0 and 
T1) and ‘treatment group’ (alpine climate and moderate maritime climate) as interaction 
terms in this model. If any statistically significant difference was detected, we obtained 
PERMANOVA coefficients to determine which genera contributed most to this change.26 
To detect changes in relative abundance within the 10 most abundant genera over time, 
we performed univariate analysis using a negative binomial generalized linear model.27
In depth analyses were performed for S. aureus and S. epidermidis by comparing log10 
transformed concentrations (fg/µL). Undetectable DNA concentrations were noted as 
equal to zero and referred to as negative. A Linear Mixed-Effect model with post hoc 
analysis was used to assess the changes in S. aureus and S. epidermidis abundance. The 
differences between both treatment groups were assessed by calculating the interaction 
between covariates ‘time point*treatment group’. This statistical model was also applied 
to Shannon diversity index.
Statistical analyses were performed in SPSS (version 21) and R software (version 3.5.1). Lin-
ear Mixed-Effect models were performed using ‘lme’ and ‘lme4’ package. Post hoc analysis 
was performed with ‘multcomp’ package and corrected for multiple testing.28, 29 We used 
the packages ‘ape’ and ‘vegan’ for MDS and PERMANOVA respectively.30 In this model, we 
accounted for repeated measurements using the ‘strata’ argument. The changes in rela-
tive abundance for the 10 most abundant genera were analyzed using package ‘DESeq2’.27 




A total of 84 patients were randomized of whom 79 patients started the intervention. Two 
patients from the moderate maritime climate group did not complete the intervention 
and sequencing data and qPCR data was missing for two other patients in this group. 
This resulted in 75 patients in our study: 38 patients in the alpine climate group and 37 
patients in the moderate maritime climate group (Figure 1). Demographic data, comor-
bidities and disease severity were not significantly different between both groups at the 
start of intervention (Table 1). The median EASI score at T0 was 39.0 (interquartile range 
(IQR) 18.7-59.3) for the alpine climate group and 40.8 (IQR 22.2-52.8) for the moderate 
maritime climate group.
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Assigned to alpine climate
N=41









Completed  interven�on (T1)
N=38
Completed  interven�on (T1)
N=39
Analyzed in this study
N=38
Analyzed in this study
N=37
Excluded (n=3)
2: delay to start interven�on
1: not willing to stay in Davos
Excluded (n=2)
1: emergency interven�on
1: travelling too �me consuming
Excluded (n=2)
2: no swabs collected
Figure 1. Flowchart of study participants
Table 1. Baseline characteristics
Alpine climate group (n=38) Maritime climate group (n=37)
sex (female), n(%) 17 (44.7) 19 (51.4)
Age, mean ± sd 13.1±2.5 12.8±2.4
Age of Ad onset < 6 months, n(%) 6 (15.8) 5 (13.5)
Asthmaa, n(%) 25 (65.8) 29 (78.4)
rhinitisb, n(%) 34 (89.5) 32 (86.5)
Food allergyc, n(%) 26 (68.4) 26 (70.3)
sA-eAsi, median (iQr) 39.0 (18.7-59.3) 40.8 (22.2-52.8)
Topical corticosteroidsd, n(%)
None 1 (2.6) 1 (2.7)
Moderate 1 (2.6) 3 (8.1)
Potent 35 (92.1) 30 (81.1)
Very potent 1 (2.6) 3 (8.1)
systemic medication, n(%)
Prednisone 3 (7.9) -
Cyclosporine 1 (2.6) 4 (10.8)
oral antibiotics, n(%) - 1 (2.7)
Positive for S. aureus, n(%)e
Lesional skin 29 (76.3) 28 (75.7)
Non-lesional skin 19 (50.0) 18 (48.6)
Positive for S. epidermidis, n(%)e
Lesional skin 35 (92.1) 36 (97.3)
Non-lesional skin 36 (94.7) 35 (94.6)
Abbreviations, AD, atopic dermatitis; SA-EASI, Self-Administered Eczema Area and Severity Index; SD, stan-
dard deviation. aAsthma was diagnosed based on spirometry reversibility testing and Methacholine Challenge 
Test. bRhinitis was diagnosed based on assessment by a pediatrician. cFood allergy was defined as a positive 
double-blind placebo-controlled food challenge (DBPCFC) or convincing clinical history (a reported Type I al-
lergic reaction with acute symptoms within 2 hours after ingestion of the food) in combination with sensitiza-




Lesional and nonlesional skin samples were collected from all 75 pati ents in this study at 
both ti me points and were analyzed using qPCR techniques. Suffi  cient amount of DNA to 
perform 16S rRNA sequencing was available at both ti me points in 49 pati ents for lesional 
skin and 45 pati ents for nonlesional skin (Figure S1). Pati ent characteristi cs of missing 
data did not diff er from the study group. A total of 1603092 sequences (median 9600; IQR 
3516-26420) were obtained from the 98 lesional samples and 1949477 sequences (me-
dian 28780; IQR 6007-347885) from the 90 nonlesional samples. All sequences belonged 
to 603 genera, of which 213 remained aft er fi ltering. The 10 most abundant genera on 
lesional and nonlesional skin, before and aft er both treatment regimens, are shown in 
Figure S2. Staphylococcus was predominant in all groups followed by the Corynebacterium 
genus and Streptococcus genus.
The eff ect of alpine climate treatment on the microbial compositi on
We visualized the microbiome separated for lesional (Figure 2) and nonlesional skin (Figure 

















Figure 2. Bray-Curti s-distance based multi dimensional scaling plot showing the microbiota of the lesional skin 
samples before and aft er the six week interventi on period in alpine climate and moderate mariti me climate
For ordinati on analysis, genus tables were standardized using square root transformati on with subsequent 
applicati on of Wisconsin double standardizati on. The change in microbiome was signifi cant for pati ents treat-
ed in alpine climate (PERMANOVA: R2=0.035, p=0.01). No signifi cant change was observed aft er moderate 
mariti me climate treatment (PERMANOVA: R2=0.011, p=0.81). Abbreviati ons: T0, before the start of the in-
terventi on period; T1, aft er six weeks of treatment.
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tween both treatment groups (PERMANOVA: lesional skin: R2=0.025, p=0.25, nonlesional 
skin: R2=0.025, p=0.22). After six weeks of alpine climate treatment, a significant shift in the 
microbiome was observed on lesional skin (PERMANOVA: R2=0.035, p=0.01), whereas no 
significant change occurred after treatment in moderate maritime climate (PERMANOVA: 
R2=0.011, p=0.81). The observed change on lesional skin after alpine climate was mainly 
driven by the Staphylococcus genus with a coefficient which was 2.7 times larger than for 
other genera (Figure S4). The interaction ‘time point*treatment group’ was not significant, 
indicating that the change in the microbiome was not significantly different affected by 
treatment protocol (p=0.19). The microbiome on nonlesional skin did not change signifi-
cantly following either treatment (Figure S3).
Compared to baseline, Shannon diversity index was significantly increased after alpine 
climate treatment on both lesional and nonlesional skin (p<0.01 and p=0.02, respectively). 
This was not observed after moderate maritime climate treatment (p=0.26 and p=0.70, re-
spectively). The change in Shannon diversity index was not significantly different between 
both treatment groups (lesional skin p=0.26, nonlesional skin p=0.07) (Figure 3).
effect of alpine climate treatment on the abundance of the 10 most abundant genera
The Staphylococcus genus showed a significant reduction in the group treated in alpine 
climate on both lesional and nonlesional skin (p<0.01). In the moderate maritime climate 
group, a significant reduction in Staphylococcus genus was found on lesional skin (p<0.01). 
The other 10 most abundant genera, as noted in Figure S2, were not significantly affected 
by both treatment regimens (Figure S5).
effect of alpine climate treatment on S. aureus and S. epidermidis
To gain more insight in the Staphylococcus genus, additional qPCR was performed to iden-
tify S. aureus and S. epidermidis. qPCR data was available for all participants and included 
in our analysis (n=75). In the total study population, 57 (76.0%) patients were positive for 
S. aureus on lesional skin at T0 (alpine climate group: n=29 (76.3%), moderate maritime 
climate group: n= 28 (75.7%), Table 1). At T1, 40 (53.3%) patients remained positive on 
lesional skin (alpine climate group: n=16 (42.1%), moderate maritime climate group: n=24 
(64.9%)). The S. aureus colonization rates were slightly lower on nonlesional skin (Table 
1). After six weeks of treatment, the decrease in S. aureus load on lesional skin was sig-
nificantly different in patients treated in alpine climate compared to moderate maritime 
climate (p=0.02)(Figure 4). After alpine climate treatment S. aureus reduced from a me-
dian of 2.6 fg/µL log10 (IQR 0.1-3.4) at T0 to 0.0 fg/µL log10 (IQR 0.0-0.9) at T1 (p<0.01), 
due to the proportion of patients with undetectable S. aureus concentration at T1. In the 
moderate maritime climate group, S. aureus decreased from a median of 2.0 fg/µL log10 
(IQR 0.3-3.0) to 1.1 fg/µL log10 (IQR 0.0-2.7) (p=0.11). On nonlesional skin, a significant 
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drop in S. aureus load was observed after treatment in alpine climate with a median of 
0.4 fg/µL log10 (IQR 0.0-2.1) at T0 and 0.0 fg/µL log10 (IQR 0.0-1.0) at T1 (p<0.01) (Figure 
S6). S. epidermidis was positive in 71 (94.7%) patients in the total study group on both 
lesional and nonlesional skin at T0, compared to 72 (96%) and 74 (98.7%) for lesional and 
nonlesional skin at T1 (Table 1). S. epidermidis load was not affected by either treatment 









A. Lesional skin B. Nonlesional skin
Moderate maritime 
climate group
Alpine climate group Moderate maritime 
climate group
Alpine climate group
Figure 3. Shannon diversity index of skin samples before and after the six week intervention period in alpine 
climate and moderate maritime climate
Shannon diversity index represents the number of different genera (richness) and how even they are distrib-
uted (evenness). The boxes represent the 25th percentile, median, and 75th percentile. Statistical analysis 
was performed using a Linear Mixed-Effect model with post-hoc analysis. A: Lesional skin samples. Com-
pared to baseline, significant differences in Shannon diversity index were found after treatment in alpine 
climate (p<0.01). No significant change was observed after moderate maritime climate (p=0.09) or between 
both treatment groups (p=0.26). B: Nonlesional skin samples. Compared to baseline, significant differences 
in Shannon diversity index were found after treatment in alpine climate (p=0.02). No significant change was 
observed after moderate maritime climate (p=0.70) or between both treatment groups (p=0.07). Abbrevia-
tions: T0, before the start of the intervention period; T1, after six weeks of treatment.
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discussion
This study showed that alpine climate treatment aff ects the microbiome on both lesional 
and nonlesional skin in children with diffi  cult to treat AD. We found a signifi cant change in 
the overall skin microbiome on lesional skin aft er six weeks of alpine climate treatment, 
whereas no signifi cant change was observed aft er moderate mariti me climate treatment. 
Moreover, a signifi cant change was observed on both lesional and nonlesional skin in 
Shannon diversity index, Staphylococcus abundance and S. aureus load in parti cular. The 
reducti on in S. aureus load was signifi cantly larger when compared to moderate mariti me 
climate.
This is the fi rst study describing the eff ect of alpine climate treatment on the skin micro-
biome in pati ents with AD. Alpine climate off ers favorable features for pati ents with AD, 
Figure 4. Quanti tati ve PCR results of the lesional skin samples for S. aureus and S. epidermidis before and aft er 
the six week interventi on period in alpine climate and moderate mariti me climate
The results for S. aureus and S. epidermidis loads are shown using log10 transformed data. A signifi cant diff er-
ence in S. aureus load was found aft er alpine climate treatment (p<0.01). S. epidermidis was stable during the 
treatment period. The decrease in S. aureus load was signifi cantly larger aft er alpine climate compared to mod-
erate mariti me climate (p=0.02). The boxes represent the 25th percenti le, median, and 75th percenti le. Dots 
represent individual samples. Stati sti cal analysis was performed using a Linear Mixed-Eff ect model with post-hoc 
analysis). Abbreviati ons: T0, before the start of the interventi on period; T1, aft er six weeks of treatment.
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including lower exposure to allergens and pollution and an increased UV-R.11, 12 Moreover, 
children treated in alpine climate were separated from their parents and intensively moni-
tored by the multidisciplinary treatment team. This treatment setting in alpine climate 
has beneficial effects on disease severity and was shown to affect the immune response 
(blood eosinophils, memory B cells, CD8+ T cells and Th2 cells).14, 18, 32 Besides effects on 
the immune system, studies also proposed that geographical variability, with variation in 
UV-R, can influence the skin barrier and the microbiome.2, 33 Although this study shows 
a change in the skin microbiome after alpine climate treatment, we cannot prove that 
the observed effect is directly caused by the alpine climate or through the effect on the 
immune system or treatment setting.
After alpine climate treatment, we found a significant increase in Shannon diversity in-
dex and a significant reduction in S. aureus load on both lesional and nonlesional skin. 
Moreover, the decrease in S. aureus load on lesional skin was significantly different from 
the maritime climate group (p=0.02). In a previous paper, describing the effectiveness 
of alpine climate treatment in this study population, a significantly larger decrease in 
disease severity was observed following alpine climate treatment than maritime climate 
treatment (p<0.01). The SA-EASI score decreased from a median of 39.0 (IQR 18.7-59.3) 
to 2.6 (IQR 0.3-6.2) and 40.8 (IQR 22.2-52.8) to 12.0 (IQR 3.6-22.1) after six-week treat-
ment in alpine climate and moderate maritime climate respectively.23 Literature shows a 
positive correlation between the abundance of Staphylococcus, in particular S. aureus, 
and disease severity in patients with AD.6-8, 34 A decrease in disease severity also leads 
to higher bacterial diversity.7 It is likely that our results are affected by the differences in 
disease severity. However, it is unknown whether the S. aureus abundance is a result or a 
cause of changes in disease severity. More studies with frequent sampling around flares 
are needed to answer this question.
Compared to lesional skin, we were not able to detect a change in the microbiome on 
nonlesional skin after alpine climate treatment. However, the changes in Shannon diver-
sity index, Staphylococcus abundance and S. aureus after alpine climate treatment were 
significant for both lesional and nonlesional skin. Nonlesional skin in AD is known to differ 
from both lesional AD skin and healthy skin.35, 36 This can be explained by the impaired 
skin barrier in patients with AD, which also affects nonlesional skin and makes it more 
susceptible to penetration of allergens and bacteria than healthy skin.37 A previous study 
investigating the effect of topical corticosteroids and bleach baths in patients with AD, also 
showed a significant change in microbial composition after treatment on lesional skin, but 
not on nonlesional skin.8 This is in line with our findings. A possible explanation can be the 
higher diversity and lower Staphylococcus abundance, compared to lesional skin, making 
changes more subtle. Another explanation can be the lesser impact of disease severity 
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and thus inflammation on this skin. Nonlesional skin might tell us more about the effect of 
climate than lesional skin which is more subject to the secondary effects of inflammation.
In this study, both lesional and nonlesional skin in AD patients were dominated by the 
Staphylococcus genus. These results support previous literature describing an excess of 
Staphylococcus, and more specific of S. aureus, in the skin microbiome of patients with 
AD.3, 7, 36 Other abundant genera included Streptococcus (known to be more present in 
children with AD) and Corynebacterium (common in healthy skin microbiome).3, 35, 38 
Looking in more depth at the Staphylococcus genus, the prevalence of S. aureus at the 
start of intervention was 76.0% and 49.3% for lesional and nonlesional skin respectively. 
These percentages are slightly higher than described in a recent meta-analysis on this 
subject and might be explained by our inclusion criteria, selecting patients with moderate 
to severe AD.39 Although patients showed a significant reduction in disease severity in this 
study, a large proportion remained positive for S. aureus on the skin (lesional T0: 76,0%, 
T1: 53,3%. Nonlesional T0: 49,3%, T1: 32,0%). These results suggest that AD symptoms are 
not only associated with the presence or absence of S. aureus, but more importantly with 
the total S. aureus load on the skin.
We did not find a significant change in S. epidermidis load in our study. The role of S. 
epidermidis in the pathogenesis of AD is still unclear and literature on this subject is con-
flicting.7, 40, 41 Due to the inhibitory effect of S. epidermidis on S. aureus, by the production 
of bacteriocins, serine protease Esp and phenol-soluble modulins, some correlation may 
be expected.42-44 In a previous study, an increase in S. epidermidis was found during a 
disease flare in patients with AD.7 In our study the quantities of S. epidermidis were stable 
over time despite a drop in S. aureus load and severity following treatment. It is possible 
that S. epidermidis is elevated in the acute stadium (flares) as a compensatory mechanism 
to control S. aureus, but in a chronic stadium these levels normalized.
This study has a pragmatic design, which makes it hard to assess what contributed most to 
the observed outcomes. A characteristic of the alpine climate group, besides the unique 
aspects of this climate, was the supervision leading to optimal treatment compliance. 
It might be that due to supervision, the application of topical corticosteroids was more 
adequately and frequent in this group and could have affected disease severity and the 
skin microbiome. Moreover, this study describes secondary outcomes of this trial and 
medication use was not applied as exclusion criteria. Previous studies showed an effect 
of medication use on the skin microbiome. However, it was not possible to discontinue 
medication use in this group of patients with difficult to treat, moderate to severe dis-
ease.8, 45 During this study, the use of medication was carefully monitored and showed no 
significant differences between both treatment groups. Results for patients using systemic 
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medication at T0 did not deviate from the rest of the study population (data not shown). 
Moreover, the proportion of patients using topical and/or systemic medication during the 
intervention was stable (Table S2).
A limitation of this study was the use of the V4 hypervariable region for sequencing. With 
this variable region it is not possible to properly detect the Propionibacterium or to clas-
sify the Staphylococci at species level. To overcome this problem for the Staphylococci, we 
determined S. aureus and S. epidermidis abundance with qPCR methods. Since the body 
sites which were mainly sampled for this study are usually low or devoid of Propionibac-
terium this should only have had a minor to negligible effect on the data presented here.2
This study encourages to perform explanatory studies with a similar treatment setting in 
both climates to confirm the effect of climate conditions alone on the skin microbiome. 
Including samples from the skin of healthy subjects in future studies might give us more 
information about the differences in the skin microbiome between AD and controls and 
assess if a decrease in disease severity (which was observed at T1) leads to a microbiome 
more comparable to healthy subjects. Furthermore, it would be interesting to assess if 
residents of moderate maritime climate and alpine climate have a distinct microbiome.
In conclusion, six weeks of treatment in the alpine climate affects the skin microbiome 
in children with difficult to treat AD which might reflect successful treatment. This study 
shows new perspectives in the potential mode of action for therapies in patients with AD 
and encourages further investigation of skin microbiome modulating therapies.
127
Alpine climate treatment and the microbiome
reFerences
 1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS. Global variations 
in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 
2009;124(6):1251-8 e23.
 2. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9(4):244-53.
 3. Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD. The role of the skin microbiome in atopic 
dermatitis: a systematic review. Br J Dermatol. 2017;177(5):1272-8.
 4. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and Atopic Dermatitis: A Complex and 
Evolving Relationship. Trends Microbiol. 2017.
 5. Travers JB. Toxic interaction between Th2 cytokines and Staphylococcus aureus in atopic dermatitis. 
J Invest Dermatol. 2014;134(8):2069-71.
 6. Clausen ML, Agner T, Lilje B, Edslev SM, Johannesen TB, Andersen PS. Association of Disease Sever-
ity With Skin Microbiome and Filaggrin Gene Mutations in Adult Atopic Dermatitis. JAMA Dermatol. 
2018;154(3):293-300.
 7. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbi-
ome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 
2012;22(5):850-9.
 8. Gonzalez ME, Schaffer JV, Orlow SJ, Gao Z, Li H, Alekseyenko AV, et al. Cutaneous microbiome ef-
fects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. J 
Am Acad Dermatol. 2016;75(3):481-93 e8.
 9. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment 
of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-60.
 10. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment 
of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176-93.
 11. Vocks E. Climatotherapy in atopic eczema. In: Ring J PB, Ruzicka T, eds. Handbook of Atopic Eczema. 
Springer-Verlag BerlinHeidelberg: Springer; 2006:507-523.
 12. Rijssenbeek-Nouwens LH, Bel EH. High-altitude treatment: a therapeutic option for patients with 
severe, refractory asthma? Clin Exp Allergy. 2011;41(6):775-82.
 13. Fieten KB, Weststrate AC, van Zuuren EJ, Bruijnzeel-Koomen CA, Pasmans SG. Alpine climate treat-
ment of atopic dermatitis: a systematic review. Allergy. 2015;70(1):12-25.
 14. Heeringa JJ, Fieten KB, Bruins FM, van Hoffen E, Knol EF, Pasmans S, et al. Treatment for moderate 
to severe atopic dermatitis in alpine and moderate maritime climates differentially affects helper T 
cells and memory B cells in children. Clin Exp Allergy. 2018.
 15. Simon D BS. The effects of high altitude climate therapy. Phys Med Rehab Kuror. 2001;11:104–9.
 16. Triebskorn A GH, Gloor M, Borelli S. Hydration of the horny layer and barrier function in atopic 
dermatitis before and after therapy in high-altitude climate. Z Hautkr. 1991:66:145–7.
 17. McBride ME, Duncan WC, Knox JM. The environment and the microbial ecology of human skin. Appl 
Environ Microbiol. 1977;33(3):603-8.
 18. Faergemann J, Larko O. The effect of UV-light on human skin microorganisms. Acta Derm Venereol. 
1987;67(1):69-72.
 19. Patra V, Byrne SN, Wolf P. The Skin Microbiome: Is It Affected by UV-induced Immune Suppression? 
Front Microbiol. 2016;7:1235.
 20. Thyssen JP, Zirwas MJ, Elias PM. Potential role of reduced environmental UV exposure as a driver of 
the current epidemic of atopic dermatitis. J Allergy Clin Immunol. 2015;136(5):1163-9.
Chapter 5.1
128
 21. Wang Y, Zhu W, Shu M, Jiang Y, Gallo RL, Liu YT, et al. The response of human skin commensal bacteria 
as a reflection of UV radiation: UV-B decreases porphyrin production. PLoS One. 2012;7(10):e47798.
 22. Fieten KB, Zijlstra WT, van Os-Medendorp H, Meijer Y, Venema MU, Rijssenbeek-Nouwens L, et 
al. Comparing high altitude treatment with current best care in Dutch children with moderate to 
severe atopic dermatitis (and asthma): study protocol for a pragmatic randomized controlled trial 
(DAVOS trial). Trials. 2014;15:94.
 23. Fieten K, Schappin R, Zijlstra W, Figee L, Beutler J, Raymakers F, et al. Effectiveness of alpine climate 
treatment for children with difficult to treat atopic dermatitis: results of a pragmatic randomized 
controlled trial (DAVOS trial). Clin Exp Allergy. 2017.
 24. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-throughput 
microbial community analysis on the Illumina HiSeq and MiSeq platforms. Isme J. 2012;6(8):1621-4.
 25. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA 
sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261-7.
 26. Gonzáles I DS, Martin P.G.P et al. CCA: An R Package to extend canonical correlation analysis., 23. 
JoSS.
 27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data 
with DESeq2. Genome Biol. 2014;15(12):550.
 28. Harrison XA, Donaldson L, Correa-Cano ME, Evans J, Fisher DN, Goodwin CED, et al. A brief introduc-
tion to mixed effects modelling and multi-model inference in ecology. PeerJ. 2018;6:e4794.
 29. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to 
Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289-
300.
 30. Oksanen J BF, Friendly M et al. The Vegan Package. Community Ecology Package. [28-02-2018]; 
Available from: https://cran.r-project.org/web/packages/vegan/vegan.pdf.
 31. Wickham H. ggplot2: Elegant Graphics for Data Analysis Springer-Verlag. 2009.
 32. Hamann CR, Andersen YMF, Engebretsen KA, Skov L, Silverberg JI, Egeberg A, et al. The effects of 
season and weather on healthcare utilization among patients with atopic dermatitis. J Eur Acad 
Dermatol Venereol. 2018;32(10):1745-53.
 33. Engebretsen KA, Johansen JD, Kezic S, Linneberg A, Thyssen JP. The effect of environmental hu-
midity and temperature on skin barrier function and dermatitis. J Eur Acad Dermatol Venereol. 
2016;30(2):223-49.
 34. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, et al. Skin colonization by Staphylococcus aureus in 
patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind 
multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680-7.
 35. Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM, et al. The skin microbiome is different 
in pediatric versus adult atopic dermatitis. J Allergy Clin Immunol. 2016;138(4):1233-6.
 36. Seite S, Flores GE, Henley JB, Martin R, Zelenkova H, Aguilar L, et al. Microbiome of affected and 
unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs 
Dermatol. 2014;13(11):1365-72.
 37. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N 
Engl J Med. 2011;365(14):1315-27.
 38. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal 
diversity of the human skin microbiome. Science. 2009;324(5931):1190-2.
 39. Totte JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and 
odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. 
Br J Dermatol. 2016;175(4):687-95.
129
Alpine climate treatment and the microbiome
 40. Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin 
of atopic dermatitis patients and from healthy subjects. Int J Dermatol. 1999;38(4):265-9.
 41. Hon KL, Tsang YC, Pong NH, Leung TF, Ip M. Exploring Staphylococcus epidermidis in atopic eczema: 
friend or foe? Clin Exp Dermatol. 2016;41(6):659-63.
 42. Sugimoto S, Iwamoto T, Takada K, Okuda K, Tajima A, Iwase T, et al. Staphylococcus epidermidis 
Esp degrades specific proteins associated with Staphylococcus aureus biofilm formation and host-
pathogen interaction. J Bacteriol. 2013;195(8):1645-55.
 43. Otto M. Staphylococcus colonization of the skin and antimicrobial peptides. Expert Rev Dermatol. 
2010;5(2):183-95.
 44. Cogen AL, Yamasaki K, Sanchez KM, Dorschner RA, Lai Y, MacLeod DT, et al. Selective antimicrobial 
action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal 
resident of the skin. J Invest Dermatol. 2010;130(1):192-200.
 45. Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P, et al. IL-4Ralpha Blockade by 
Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































no topical corticosteroida, n(%)
T0 1 (2.6) 1 (2.7)
T1 3 (8.1) -
Moderate topical corticosteroida, n(%)
T0 1 (2.6) 3 (8.1)
T1 5 (13.2) 7 (18.9)
Potent topical corticosteroida, n(%)
T0 35 (92.1) 30 (81.1)
T1 30 (78.9) 27 (73.0)
Very potent topical corticosteroida , n(%)
T0 1 (2.6) 3 (8.1)
T1 - 3 (8.1)
Prednisone, n(%)
T0 3 (7.9) -
T1 - -
cyclosporine, n(%)
T0 1 (2.6) 4 (10.8)
T1 - 1 (2.7)
oral antibiotics , n(%)
T0 - 1 (2.7)
T1 - 1 (2.7)































Figure s1. Flowchart showing the number of patients included in our statistical analysis
Samples containing insufficient amounts of DNA did not result in usable sequence data and were therefore 
omitted. Only the patients with available data at both time points were included in this study.
135




















































































































































































































































































































































































































































































































































Figure s3. Bray-Curti s-distance based multi dimensional scaling plot showing the microbial communiti es of the 
nonlesional skin samples before and aft er the six week interventi on period in alpine climate and moderate 
mariti me climate
For ordinati on analysis, genus tables were standardized using square-root transformati on with subsequent 
applicati on of Wisconsin double standardizati on. No signifi cant changes were found aft er both treatment 
regimens.  Alpine climate group (PERMANOVA R2=0.026,  p=0.15), moderate mariti me climate group (PER-
MANOVA R2=0.018, p=0.23). Abbreviati ons: T0, before the start of the interventi on period; T1, aft er six weeks 
of treatment.  
 
 









Mitochondria genus incertae sedis
Staphylococcus
Figure s4. Top 10 genera driving the change in microbial compositi on on lesional skin aft er alpine climate 
treatment
The x-axis displays coeffi  cients that represent the contributi on of a certain genus to the change in microbial 
compositi on on lesional skin aft er alpine climate treatment. The contributi on of the Staphylococcus genus was 
2.7 ti mes larger than for other genera.
137






































































Alpine climate Moderate maritime 
climate
Alpine climateModerate maritime 
climate
Alpine climate Moderate maritime 
climate
Alpine climate
Treatment group Treatment group
Figure s5. Change in relative abundance for the 10 most abundant genera before and after the six week inter-
vention period in alpine climate and moderate maritime climate
Genus counts were normalized using DESeq regularized-logarithm transformation. Statistical analysis was 
performed using univariate analysis using a negative binomial generalized linear model. The Staphylococcus 
genus showed a significant reduction in the group treated in alpine climate on both lesional and nonlesional 
skin (both p<0.01). In the moderate maritime climate group, a significant reduction in Staphylococcus genus 
was found on lesional skin (p<0.01).
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Figure s6. qPCR results of the nonlesional skin samples for S. aureus and S. epidermidis before and after the 
six week intervention period in alpine climate and moderate maritime climate
The results for S. aureus and S. epidermidis load are shown using log10 transformed data. A significant dif-
ference in S. aureus load was found after alpine climate treatment (p<0.01). The boxes represent the 25th 
percentile, median, and 75th percentile. Dots represent individual samples. Statistical analysis was performed 
using a Linear Mixed-Effect model with post-hoc analysis. Abbreviations: T0, before the start of the interven-
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Targeted anti-staphylococcal therapy in atopic dermatitis
To the Editor:
Staphylococcus (S.) aureus density is increased in many patients with atopic dermatitis 
(AD) and is thought to contribute to the disease pathogenesis, interacting with an altered 
skin barrier and immunological changes.1 S. aureus might induce or aggravate inflamma-
tion via different mechanisms, for example through excretion of virulence factors, even 
if the S. aureus overgrowth is primarily caused by other factors.2 Current guidelines only 
recommend antimicrobial therapy directed against S. aureus in clinically infected AD based 
on a Cochrane review where no clinical benefit of short-term antimicrobial treatment in 
non-infected AD was found.3
Arguably, long-term anti-staphylococcal treatment, such as antibiotics, might reduce 
symptoms in AD.4 However, this is undesired because antibiotics can affect the commensal 
microbiota and could induce bacterial resistance.5 In contrast, long-term treatment of AD 
with an endolysin that targets only S. aureus is feasible. It might improve AD symptoms 
and reduce the use of corticosteroids consecutively.2, 6 Therefore, we aimed to determine 
the topical corticosteroid (TCS)-sparing effect and safety of 12 weeks of endolysin treat-
ment against S. aureus in patients with AD.
We performed a double-blind, vehicle-controlled superiority trial (MAAS trial, Clinical-
Trials.gov NCT02840955) in 100 adult patients with TCS-treated, not clinically infected, 
moderate to severe AD, which was defined by an Eczema Area and Severity Index (EASI) 
of 7.1 to 50.0. After a two-week run-in period to standardize the TCS treatment with 
triamcinolone acetonide 0.1% cream, patients were randomly assigned 1:1 to a 12-week 
intervention with either a topical endolysin against S. aureus or a vehicle twice daily, 
followed by an eight-week follow-up period. The vehicle and recombinant chimeric en-
dolysin, Staphefekt™ SA.100, were provided by Micreos Human Health (Bilthoven, The 
Netherlands) and topically applied in a cetomacrogol cream. Details on patient inclusion, 
randomization, and study procedures at six assessments are described in a previously 
published study protocol (Figure S1).2
The primary outcome, the TCS-sparing effect of endolysin treatment against S. aureus, 
was evaluated by the patients, who registered daily use of a TCS (yes/no) over 12 weeks. 
Secondary outcomes included differences in TCS use measured in grams, clinical efficacy, 
quality of life using the Skindex-29, S. aureus load on the skin, and safety and tolerability 
of endolysin treatment. Clinical efficacy was measured using the EASI, Investigators Global 
Assessment, Patient-Oriented Eczema Measure, pruritus Numeric Rating Scale, and by 
registration of the number of flares. The S. aureus load on the skin was assessed by a semi-
quantitative culture and quantitative polymerase chain reaction (qPCR, Appendix S1).
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Generalized linear mixed-effect models for repeated measurements were used to analyze 
the primary and dichotomous secondary outcomes, and linear mixed-effect models were 
used for continuous secondary outcomes. Data were analyzed as intention-to-treat and 
per-protocol. Furthermore, a subgroup analysis was performed in patients with a positive 
S. aureus skin culture at two time points before start of the intervention.
Eighty-eight (88.0%) patients completed the intervention, and 87 (87.0%) completed 
follow-up (13% dropout rate, Figure S2). Patients’ characteristics were comparable be-
tween the endolysin and vehicle groups (Table 1). Over the 12-week intervention period 
(corresponding to 8400 days for 100 patients), patients in the endolysin group used a TCS 
for 1889 (45.0%) days compared with 1566 (37.3%) days in the vehicle group. There was 
no statistically significant difference in the probability of TCS use per day between the 
groups in the intention-to-treat analysis, per-protocol analysis, and in the subgroup of S. 
aureus-positive patients (p = 0.97, p = 0.40 and p = 0.08, respectively, Table 2). Sensitivity 
analyses showed no differences in the odds ratio of TCS use per assessment day. Except 
for the number of doctor-reported AD flares during the intervention period (per-protocol, 
n=2 in endolysin group vs. n=10 in vehicle group, p = 0.03), no statistically significant 
differences were found in the secondary outcomes after both intention-to-treat and per-
protocol analyses (Table S1 and S2). At baseline, 62 (64.6%) patients had positive results 
for S. aureus based on skin culture and 24 (24.7%) by qPCR. Both methods showed no 
significant difference in S. aureus reduction (Table S3 and S4). During the study, one seri-
ous adverse event occurred in the endolysin group eight weeks after the last application 
of endolysin cream (pleural effusion with hospitalization), which was considered unlikely 
to be related to the study intervention (Table S5 and S6).
Our results are in accordance with data from a Cochrane review showing no significant 
effect of short-term anti-S. aureus therapy in patients with non-infected AD.3 We cannot 
confirm the positive results of other longer-term studies. However, these studies used 
broad-spectrum antimicrobials and mainly included patients with signs of bacterial infec-
tion.4 Patients with clinically infected AD were excluded from our study, and a possible 
effect of anti-S. aureus endolysins in this patient group should be determined in future 
studies.
Several hypotheses could explain our results. First, use of triamcinolone in the run-in phase 
resulted in a decrease in AD severity (Table 1), which might have masked a possible benefit 
of endolysin treatment. Second, daily use of an emollient and good compliance with the 
treatment could have resulted in a reduction of triamcinolone use in both the endolysin 
and vehicle groups.7 Because AD is a heterogeneous disease, anti-S. aureus treatment 
might not be suitable for all patients with AD, indicating the need for subphenotyping. 
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Table 1. Baseline characteristics
Total (n=100) endolysin (n=50) Vehicle (n=50)
Age
years; median (IQR) 33.5 (25.5-47.5) 36.5 (25.0-51.0) 32.5 (24.0-44.0)
sex (male)
n (%) 55 (55.0) 24 (48.0) 31 (62.0)
race, n (%)
American Indian or Alaska Native 5 (5.0) 2 (4.0) 3 (6.0)
Asian 10 (10.0) 2 (4.0) 8 (16.0)
Black or African American 8 (8.0) 5 (10.0) 3 (6.0)
White 77 (77.0) 41 (82.0) 36 (72.0)
Atopic disease, n (%)
Food allergy 43 (43.0) 18 (36.0) 25 (50.0)
Rhinoconjunctivitis 63 (63.0) 28 (56.0) 35 (70.0)
Asthma 47 (47.0) 25 (50.0) 22 (44.0)
eAsi, median (iQr)
Screening (V1) 12.9 (9.2-19.0) 13.7 (8.9-19.1) 12.5 (9.2-19.0)
Baseline (V2) 8.0 (5.0-13.5)a 8.3 (5.0-14.7)b 8.0 (4.9-12.9)c
iGA, median (iQr)
Baseline (V2) 2.0 (2.0-3.0)a 2.0 (2.0-3.0)b 2.0 (2.0-3.0)c
PoeM, mean (sd)
Baseline (V2) 12.9 (6.2)a 14.5 (8.3-17.0)b 13.0 (8.0-15.0)c
Pruritus nrs, median (iQr)
Baseline (V2) 3.0 (2.0-4.0)a 3.0 (2.0-4.0)b 3.0 (2.0-4.0)c
skindex-29, mean (sd)
Baseline (V2) 35.1 (17.1)a 37.3 (15.3)b 32.9 (18.7)c
use of topical corticosteroids at screening, n (%)    
Class 1 3 (3.0) 1 (2.0) 2 (4.0)
Class 2 13 (13.0) 6 (12.0) 7 (14.0)
Class 2-3 11 (11.0) 3 (6.0) 8 (16.0)
Class 3 44 (44.0) 22 (44.0) 22 (44.0)
Class 3-4 3 (3.0) 2 (4.0) 1 (2.0)
Class 4 18 (18.0) 11 (22.0) 7 (14.0
Unknown 8 (8.0) 6 (12.0) 4 (8.0)
S. aureus skin cultured, n (%)
Positive 56 (56.0) 32 (64.0) 24 (48.0)
Intermediate 20 (20.0) 7 (14.0) 13 (26.0)
Negative 20 (20.0) 9 (18.0) 11 (22.0)
Missing 4 (4.0) 2 (4.0) 2 (4.0)
Abbreviations: EASI, Eczema Area and Severity Index; IGA, Investigators Global Assessment; IQR, interquartile 
range; NRS, Numeric Rating Scale; POEM, Patient Oriented Eczema Measure; SD, standard deviation, S. au-
reus, Staphylococcus aureus. Missings: an=3 (3.0%), bn=2 (4.0%), cn=1 (2.0%). dPositive is defined as having a 
positive culture at visit 1 and visit 2a; intermediate is defined as having one positive culture and one negative 
culture at visit 1 and visit 2a; negative is defined as having two negative cultures at visit 1 and visit 2a.
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Because only 56% of our study population had two consecutive positive S. aureus skin 
cultures (indicating persistent colonization) before start of the intervention, the target 
population that would probably benefit the most from endolysin treatment was small.
Our data suggest that endolysin treatment has no effect on S. aureus in vivo. However, 
patients might have been recolonized with S. aureus from the nose because 73% of them 
were nasal carriers (data not shown). Alternatively, cetomacrogol as the basis of the en-
dolysin cream might have created a barrier on the skin that prevented the endolysin to 
reach and subsequently kill S. aureus. However, some reduction in S. aureus load would 
have been expected in both treatment groups because of the use of TCSs and emollients 
in this study, which both have been shown to reduce the S. aureus load on the skin.8, 9 
Nonetheless, it is unclear whether complete eradication of S. aureus is required for clinical 
improvement because a case series showed a clear clinical improvement without S. aureus 
reduction using a qualitative culture in S. aureus-related dermatoses.6 In addition, the 
discrepant results between culture and qPCR indicate the complexity of the interpretation 
of S. aureus testing. Despite the limitations and outcome, this study provides estimates of 
Table 2. Generalized Linear Mixed-Effect model results for the difference in topical corticosteroid use per day 
during the 12-week intervention period
Analysis Time period 
or time point 
in days from 
baseline
Patients included in 
analysis
Topical corticosteroid 
use ‘yes’, n (%)
or (95% ci) P-valuea
endolysin, 
n







14 40 37 26 (65.00) 20 (54.05) 0.99 (0.95 – 1.03) 0.49
42 37 37 26 (70.27) 22 (59.46) 0.99 (0.78 – 1.24) 0.91




14 22 21 14 (63.64) 10 (47.62) 1.09 (0.98 – 1.21) 0.10
42 17 18 12 (70.59) 11 (61.11) 1.36 (0.84 – 2.20) 0.21




14 26 16 17 (65.38) 7 (43.75) 0.87 (0.78 – 0.96) 0.01
42 22 17 16 (72.73) 8 (47.06) 0.85 (0.49 – 1.48) 0.56
84 18 15 11 (61.11) 11 (73.33) 1.29 (0.84 – 1.96) 0.24
Given the low number of patients using escape medication (n=5), we did not correct for its use. aOverall effect 
of endolysin treatment during intervention period was calculated with a Likelihood-Ratio test, the effect per 
time point using a Wald test with t-distribution. bDefined as having a positive culture both at visit 1 and visit 2a 
(endolysin n=32, vehicle n=24). Sensitivity analyses, performed by adding/subtracting 0.25 times the standard 
deviation to/of the odds, showed no differences in the odds ratio of topical corticosteroid use per assessment 
day. Abbreviations: S. aureus, Staphylococcus aureus
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AD symptoms, use of TCSs, and the percentage of persistent S. aureus carriers that can be 
used for future clinical studies.
In conclusion, long-term targeted endolysin treatment against S. aureus in this study was 
well tolerated but had no TCS-sparing effect in patients with AD. However, an effect cannot 
be excluded because good compliance with the treatment and concurrent application of 




 1. Totte JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and 
odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. 
Br J Dermatol. 2016;175(4):687-95.
 2. Totte J, de Wit J, Pardo L, Schuren F, van Doorn M, Pasmans S. Targeted anti-staphylococcal therapy 
with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbi-
ome: study protocol for a randomized controlled trial (MAAS trial). Trials. 2017;18(1):404.
 3. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococ-
cus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 
2010;163(1):12-26.
 4. Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with 
moderate to severe atopic dermatitis in Malaysia. J Dermatol. 2013;40(11):874-80.
 5. Niebuhr M, Mai U, Kapp A, Werfel T. Antibiotic treatment of cutaneous infections with Staphylococ-
cus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. 
Exp Dermatol. 2008;17(11):953-7.
 6. Totté JEE, van Doorn MB, Pasmans S. Successful Treatment of Chronic Staphylococcus aureus-
Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases. Case Rep 
Dermatol. 2017;9(2):19-25.
 7. Ng JP, Liew HM, Ang SB. Use of emollients in atopic dermatitis. J Eur Acad Dermatol Venereol. 
2015;29(5):854-7.
 8. Angelova-Fischer I, Neufang G, Jung K, Fischer TW, Zillikens D. A randomized, investigator-blinded 
efficacy assessment study of stand-alone emollient use in mild to moderately severe atopic derma-
titis flares. J Eur Acad Dermatol Venereol. 2014;28 Suppl 3:9-15.
 9. Gonzalez ME, Schaffer JV, Orlow SJ, Gao Z, Li H, Alekseyenko AV, et al. Cutaneous microbiome ef-
fects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. J 
Am Acad Dermatol. 2016;75(3):481-93 e8.
149
Targeted anti-staphylococcal therapy in atopic dermatitis
suPPleMenTAry MATeriAl
Appendix s1. Microbial methods
a. Microbial sampling methods
Samples of the skin were collected using sterile Copan 490CE.A swabs for culture analysis 
and skin scrubs for qPCR analysis. Skin swabs were collected from a skin lesion at the 
first visit, preferably located at the antecubital fold or the popliteal fold. For all consecu-
tive visits the swab was collected from the location chosen at the first visit. The scrubs 
were collected from the lower arm, adjacent to the antecubital fold according to methods 
described previously.23 Scrub samples were stored at -80 ᵒC.
b. Semi-quantitative culture and qPCR for S. aureus
Bacterial cultures were performed using routine diagnostic culture procedures, using 
blood agar plates and specific S. aureus culture plates (ChromID S. aureus Elite agar 
(SAIDE), Biomérieux, France) for overnight incubation and subsequent species determina-
tion by MALDI-TOF (Bruker Daltonics, Bremen, Germany). For DNA isolation 150 µl from 
the sample was added to 350 µl lysis buffer, 500 µl Phenol (Tris pH 8) and 500 µl 0.1 mm 
zirconium beads. This mixture was mechanically disrupted by bead beating twice for 2 
minutes, followed by centrifuging for 10 minutes at 1690 RCF to separate the aqueous and 
phenolic phases. The aqueous phase was purified using AGOWA mag Mini DNA isolation 
kit. After elution, we used qPCR to determine the total load of S. aureus with the following 
primers and probes: 16S-S.aur-F1 (5’-GCG AAG AAC CTT ACC AAA TCT TG-3’), 16S-S.aur-R1 
(5’-TGC ACC ACC TGT CAC TTT GTC-3’), 16S-S.aur MGB Taqman® probe (5’-CAT CCT TTG 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































endolysin, n (%)b Vehicle, n (%)c P-valued
intention-to-treat Yes 6 (12.5) 4 (8.3) 0.74
No 42 (87.5) 44 (91.7)
Abbreviations: S. aureus, Staphylococcus aureus. aDecrease is defined as a decrease of at least 1 point on 
semi-quantitative scale (scale ranges from 0-4). bPatients included in analysis in endolysin group: n=49. cPa-
tients included in in analysis in vehicle group: n=48. dP-values were calculated using a Fisher’s Exact test for 
categorical data.
Table s4. Results for the difference in reduction of S. aureus from baseline determined by qPCR
Analysis Time period log10 reduction in qPcr for S. aureus P-valuea
endolysin, n (%) Vehicle, n (%)
intention-to-treatb Visit 2a to visit 3







Per-protocolc Visit 2a to visit 3







S. aureus positived,e,f Visit 2a to visit 3







Abbreviations: S. aureus, Staphylococcus aureus; qPCR, quantitative polymerase chain reaction. aP-values 
were calculated using a Fisher’s Exact test for categorical data. bPatients included in endolysin and vehicle 
group: visit 2a to visit 3, n=47 and n=47; visit 2a to visit 5, n=44 and n=44. cPatients included in endolysin and 
vehicle group: visit 2a to visit 3, n=25 and n=29; visit 2a to visit 5, n=16 and n=15. dPatients included in endo-
lysin and vehicle group: visit 2a to visit 3, n=9 and n=13; visit 2a to visit 5, n=9 and n=12. eAnalysis additionally 
to analyses described in the study protocol. fS. aureus positive is defined as having a positive qPCR at visit 2a 
(endolysin group n=10, vehicle group n=14). Missings: gn=1 (2.1%), hn=1 (2.3%), in=1 (6.7%).
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Table s5. Incidence of (non-) Treatment Emergent Adverse Events – Overall and per study phase










overall (V1-V6) 83 (83.0) 183 43 (86.0) 96 40 (80.0) 87
run-in (V1-V2)
At least 1 non-TEAE 21 (21.0) 27 11 (22.0) 14 10 (20.0) 13
At least 1 serious non-TEAE 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
At least 1 non-TEAE leading to 
study discontinuation
0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
At least 1 non-TEAE leading to 
death
0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
intervention (V2-V5) 
At least 1 TEAE 73 (73.0) 125 36 (72.0) 67 37 (74.0) 58
At least 1 serious TEAE 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
At least 1 TEAE leading to study 
discontinuation
3 (3.0) 3 1 (2.0) 1 2 (4.0) 2
At least 1 TEAE leading to death 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Follow-up (V5-V6)
At least 1 TEAE 25 (25.0) 31 15 (30.0) 15 10 (20.0) 16
At least 1 serious TEAE 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
At least 1 TEAE leading to study 
discontinuation
1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
At least 1 TEAE leading to death 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0




Table s6. Overall incidence of Treatment Emergent Adverse Events specified










Any Treatment emergent Adverse 
event
83 (83.0) 183 43 (86.0) 96 40 (80.0) 87
infectious diseases (including 
bacterial, viral and fungal infections)
47 (47.0) 65 26 (52.0) 40 21 (42.0) 25
Common cold 26 (26.0) 29 18 (36.0) 20 8 (16.0) 9
Dental inflammation 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Ear infection 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
Influenza 15 (15.0) 15 7 (14.0) 7 8 (16.0) 8
Herpes labialis 5 (5.0) 6 3 (6.0) 4 2 (4.0) 2
Impetiginized dermatitis 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Joint and muscle inflammation 3 (3.0) 3 2 (4.0) 2 1 (2.0) 1
Ophthalmic infection 7 (7.0) 7 4 (8.0) 4 3 (6.0) 3
Pneumonia 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Allergies 6 (6.0) 6 0 (0.0) 0 6 (12.0) 6
Food allergy 1 (1.0) 1 0 (0.0) 0 1 (2.0) 13
Allergic rhinoconjunctivitis 3 (3.0) 3 0 (0.0) 0 3 (6.0) 2
Allergic rash 2 (2.0) 2 0 (0.0) 0 2 (4.0) 2
Metabolic/endocrine/nutritional 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Musculoskeletal 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Joint and muscle pain 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Lower back pain 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
dermatologic 24 (24.0) 26 13 (26.0) 14 11 (22.0) 12
Culicosis 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Dermatomycosis 5 (5.0) 5 4 (8.0) 4 1 (2.0) 1
Hyperkeratotic eczema of the 
hands
2 (2.0) 2 2 (4.0) 2 0 (0.0) 0
Intertrigo 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
Local dry skin 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Papules 2 (2.0) 2 2 (4.0) 2 0 (0.0) 0
Paronychia 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Perioral dermatitis 2 (2.0) 2 0 (0.0) 0 2 (4.0) 2
Pustulosis 6 (6.0) 6 3 (6.0) 3 3 (6.0) 3
Rosacea 2 (2.0) 2 0 (0.0) 0 2 (4.0) 2
Skin lesions of unknown origin 2 (2.0) 2 0 (0.0) 0 2 (4.0) 2
Tinea versicolor 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
heenTa 5 (5.0) 5 2 (4.0) 2 3 (6.0) 3
Increased eye pressure 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Tinnitus 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
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Table s6. Overall incidence of Treatment Emergent Adverse Events specified (continued)










Tooth extraction 3 (3.0) 3 1 (2.0) 1 2 (4.0) 2
respiratory 5 (5.0) 5 3 (6.0) 3 2 (4.0) 2
Breathing problems 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
Dyspnea 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
Exacerbation asthma 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Pleural effusion 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
cardiovascular 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Gastrointestinal/Hepatic 6 (6.0) 6 3 (6.0) 3 3 (6.0) 3
Gastroenteritis 6 (6.0) 6 3 (6.0) 3 3 (6.0) 3
Genitourinary/renal 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
neurologic 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Headache 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Psychiatric/Psychosocial 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Depression 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Gynaecologic/obstetric 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
Non-specific menstrual complaints 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
skin symptoms after application of 
study medication
45 (45.0) 48 21 (42.0) 23 24 (48.0) 25
Local reaction after application of 
study medication (e.g. wounds, 
itch, irritated skin)
45 (45.0) 48 21 (42.0) 23 24 (48.0) 25
other 14 (14.0) 15 8 (16.0) 8 6 (12.0) 7
Bruises 1 (1.0) 1 0 (0.0) 0 1 (2.0) 1
Fatigue 2 (2.0) 2 1 (2.0) 1 1 (2.0) 1
Malaise 11 (11.0) 12 7 (14.0) 7 4 (8.0) 5
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Atopic dermatitis (AD) is the most common inflammatory skin disease, with a great impact 
on the quality of life of both patients and their families. Both the pathophysiology and 
the clinical presentation of AD are highly heterogeneous due to underlying changes in the 
microbial composition, an impaired skin barrier and an altered immunological response. 
Although multiple risk factors and key pathogenic aspects have been identified for AD, 
it remains largely unknown how these mechanisms interact and how they result in the 
inflammation as seen in AD. Increasing insights into the various mechanisms underlying 
AD may help to develop preventive and therapeutic interventions. The aim of this thesis 
was to gain more insight into the role of the main players in the pathophysiology of AD. In 
particular, we focused on (i) the microbiome, characterized by increased Staphylococcus 
(S.) aureus abundance and (ii) skin barrier defects caused by mutations in the filaggrin 
gene (FLG). This chapter provides a general overview of the main findings and clinical 
implications, considering methodological considerations. In addition, we suggest direc-
tions for future research.
THe role oF S. aureuS in THe PATHoGenesis oF Ad
Higher S. aureus colonization rates in AD patients have been known for a long time. 
However, it remains a topic of discussion whether S. aureus is actively involved in AD 
development or is merely a consequence of AD-related skin alterations that are caused by 
both physical barrier and immunological defects. Studies investigating whether S. aureus 
colonization precedes the clinical diagnosis of AD show conflicting results.1-4 Although 
some studies showed associations between early S. aureus colonization and subsequent 
development of AD, this does not prove causality.4 As described in Chapter 1, the skin 
microbiome, skin barrier and immune system form a well-balanced eco-system that con-
tributes to the mechanical and immunological barrier function of the skin. Any dysfunc-
tion in one of the three elements will lead to downstream effects in the other elements, 
causing inflammation characteristic of AD. These interactions were also demonstrated 
in recent AD studies that observed a decrease in S. aureus abundance after treatment 
with corticosteroids or coal tar, that do not have any antimicrobial properties.5, 6 It can 
be hypothesized that skin barrier defects and immunological changes occur well before 
diagnosis and lead to increased S. aureus colonization.
Although S. aureus colonization might not be the primary cause in the pathogenesis of 
AD, there is evidence that S. aureus can aggravate skin barrier damage and inflammation 
by the secretion of virulence factors, including surface proteins and toxins (Chapter 1). 
However, this bacterium can be present both as human commensal organism and as a 
pathogen causing inflammation.7 Literature on the mechanisms that enable S. aureus to 
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transform from commensal colonizer to a pathogenic organism in AD is lacking. We aimed 
to further investigate the role of  S. aureus in the pathogenesis of AD and to assess the 
effect of treatment interfering with the skin microbiome.
S. aureus strain diversity in AD
One of the discussed topics is whether AD patients are colonized by different S. aureus 
strains as compared to the general population. In addition, it has been suggested that 
specific S. aureus strains are associated with a more severe disease and that temporal 
variation in colonizing strain can aggravate inflammation.8, 9 However, literature on this 
topic is contradicting.9-12
In Chapter 2, S. aureus strains from both nose and skin were characterized using the 
spa-typing technique in 96 adult AD patients. Temporal variation in colonizing strain was 
investigated over the course of two weeks, in which treatment was standardized with 
topical corticosteroids (TSC), and links to disease severity were examined. Our results 
showed a great strain heterogeneity among the AD patients, comparable to the general 
population. Interestingly, the intra-individual variation was small, with the majority of the 
individual patients colonized by the same spa-type in both nose and skin, as well as after 
a two-week treatment period that improved the clinical symptoms. No predominant spa-
type nor temporal variation was associated with more severe disease.
Our results were in line with previous publications investigating the genetic composition 
of S. aureus, concluding that there are no specific S. aureus strains colonizing AD patients 
compared to the general population.10, 11 In addition, our results were in agreement with 
previous studies that did not show correlations between S. aureus strains and disease se-
verity.12, 13 Of important notice is that genetic diversity between strains can be missed with 
spa-typing since it is based on a single gene. Whole-genome sequencing (WGS) allows a 
more detailed analysis of the relationship between strains.14 Nonetheless, a recent study 
in pediatric AD patients, using WGS to discriminate between S. aureus strains, showed 
results that were similar to our findings.15 During disease flares, an increased growth of 
the endogenous S. aureus strain was observed. This strain was unique per patient, con-
firming the individuality of strains per patient that is likely affected by host, genetic and 
environmental factors.16
lessons learned from treatment affecting the microbiome
We can learn a lot about the pathogenesis in AD from evaluating the effect of its treat-
ment. As mentioned above, previous agents without specific anti-microbial effects led to a 
reduction in S. aureus abundance by dampening inflammation and restoring the skin bar-
rier function.5, 6  This is in line with results from our thesis. In chapter 2 and 5.2 we showed 
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that treatment with TCS in 100 adult AD patients led to a significant reduction in disease 
severity and S. aureus load. In addition, children with difficult to treat AD that were ran-
domized to treatment in alpine climate (Chapter 5.1), showed that clinical improvement 
was accompanied by a reduction in S. aureus abundance on both lesional and nonlesional 
skin. We also observed that complete eradication of S. aureus was not needed for disease 
control. These results suggest that S. aureus can be present on AD skin without causing 
overt inflammation and that increased abundance is associated with pathogenicity.6, 17
By specifically targeting S. aureus on the skin of patients with AD, we might learn how a 
reduction and/or eradication of S. aureus affects the clinical symptoms in AD. In Chapter 
5.2, we evaluated the effect of treatment with an endolysin that selectively targets S. 
aureus in adult AD patients with clinically non-infected AD. After a two-week run-in period 
to standardize TCS treatment, 100 patients were assigned to a 12-week intervention with 
topical endoloysin or placebo. In this study we did not observe a reduction in S. aureus 
abundance, the use of TCS or clinical disease severity scores. Based on these results we 
could not further unravel the contribution of S. aureus to the pathogenesis of AD. Our re-
sults can be explained by several hypotheses that should be considered in future studies. 
First, the use of TCA and emollients in the run-in phase resulted in a significant decrease in 
AD severity, which could have masked a possible benefit of endolysin treatment. Second, 
since only 56% of the patients were persistently colonized by S. aureus before the start of 
intervention, the group of patients that would possibly benefit most from this treatment 
was small. Third, both the pathogenesis and clinical symptoms in AD are highly hetero-
geneous. Therefore, it is possible that not all AD patients benefit from treatment that 
reduces and/or eradicates S. aureus on the skin.
THe role oF FLG skin bArrier deFecTs in THe PATHoGenesis 
oF AD
FLG mutations are a significant risk factor for the development of AD (odds ratio (OR) of 
3.12).18 However, FLG mutations are neither necessary nor sufficient to develop AD. This 
can be demonstrated by the prevalence estimates in the study cohorts that were included 
in this thesis. Chapter 3.1 included 358 non-AD children of the Generation R cohort, of 
which 6% had a mutation in FLG.19 The prevalence of mutation carriers in AD patients 
ranged from 16% in the 103 AD children of the Generation R cohort (Chapter 3.2) to 40% 
in the 77 children of the DAVOS cohort (Chapter 3.1). The difference in the prevalence 
estimates is also indirect evidence that FLG mutations are associated with a distinct phe-
notype. Namely, the Generation-R children were a sample of the general population in 
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which we expect most children to have mild AD, whereas the children in the DAVOS study 
were included based on having difficult to treat AD.
Indeed, numerous studies have associated FLG mutations with AD and show that a muta-
tion in this gene predisposes for early onset AD that persists into adulthood, increased AD 
severity and other allergic conditions (i.e., food allergies, asthma, and allergic rhinitis).20-22 
The exact mechanisms contributing to this disease modification effect remain largely 
unknown. Therefore, we aimed to investigate whether FLG mutations lead to alterations 
in the microbiome and/or immune cell composition, contributing to the symptoms in AD. 
In addition, we investigated the use of a non-invasive biomarker to stratify patients based 
on FLG mutation status.
FLG mutations and the microbiome in Ad
In Chapter 3.1, we investigated the association between FLG genotypes and the microbi-
ome composition of the nose, lesional and nonlesional skin in 79 children with difficult to 
treat AD. We showed that the overall microbial composition was significantly affected by 
the sampled niche (nose, lesional skin, nonlesional skin) and FLG mutation status (wild 
type vs. mutation carriers). We also performed subgroup analyses to investigate the effect 
of FLG mutation status on the microbiome in each separate niche. Within the nose, le-
sional and nonlesional skin separately, no significant association with FLG mutation status 
was found. Shannon diversity and S. aureus abundance were significantly affected by the 
niche, but not by the presence of a FLG mutation.
The absence of associations between FLG mutation status and S. aureus load was some-
what surprising in comparison to previous in vitro studies.23-25 FLG is mainly thought to 
exert its effect through the production of natural moisturizing factor (NMF) in the stratum 
corneum (SC).26 In vitro studies have shown that decreased NMF led to increased skin 
pH and altered corneocyte adhesion, that facilitated colonization by S. aureus.23-25 Clinical 
studies investigating whether S. aureus colonization is more common in FLG mutation car-
riers compared to wild-type AD patients, showed conflicting results.25, 27-30 Until now, one 
previous study investigated the association between FLG mutation status and the entire 
bacterial microbiome on the skin and in the nasal cavity.31 Within this population of 56 
adult AD patients, the microbiome on the nonlesional skin was significantly associated 
with FLG genotype.31
The results from our study indicated that there was only a small effect for FLG mutation 
status and/or that there was a lack of statistical power to identify differences in the sub-
group analyses. Another possible explanation for the results in our study and the varying 
results among clinical AD studies, is the presence of other  factors that affect filaggrin 
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expression and contribute to the barrier defect in AD. Especially disease severity has been 
shown to downregulate the levels of NMF in both lesional and nonlesional skin through 
the overexpression of T helper (Th)22 cytokines.32 As the vast majority of the children in 
the DAVOS trial had severe or very severe disease at the moment of microbiome sampling, 
filaggrin expression was likely downregulated in both FLG mutant carriers and wild-type 
patients.
FLG mutations and T- and b-cell subsets in the general pediatric population and in 
children with Ad
Chapter 3.2 has been the first study that investigated the impact of FLG mutation status 
on circulating immune cell numbers in a general pediatric population. Common FLG muta-
tions (2282del4, R2447*, R501* and S3247*) and T- and B-cell subsets were determined in 
a population-based birth cohort study (Generation R), including 523 children of European 
genetic ancestry and a subgroup of 102 AD patients, selected by parental questionnaires.
In this general pediatric population, we observed higher Th22 cell numbers in children with 
a mutation in FLG. This finding might represent the immunological response to an altered 
skin barrier caused by FLG mutations. Interestingly, other than the findings in Chapter 
3.2, increased numbers of Th22 cells have also been observed in the skin and circulation 
of patients with AD.33, 34 As IL-22 contributes to the skin integrity and the defense against 
pathogens, we hypothesized that the increased Th22 cell numbers might contribute to 
skin homeostasis to prevent further inflammatory processes leading to AD.35, 36 Another 
theory is that the higher Th22 could represent some level of inflammation without ap-
parent clinical AD symptoms as is seen in nonlesional skin. However, more studies are 
needed to further elucidate the effect of skin barrier defects on immune cells in the skin 
and circulation, and the role of  Th22 in both AD and non-AD children.
In the subgroup of children with AD, no associations between FLG mutation status and 
T- and B-cell subsets were found. This was an interesting finding since FLG mutations allow 
increased penetration of irritants, antigens and allergens into the epidermis where they 
can interact with antigen-presenting cells and provoke an immunological response.37 In 
addition, previous case series with a maximum of six adult AD patients, showed increased 
thymus-emigrated regulatory T (Treg) cells, Th2 and Th17 in the circulation of FLG mu-
tation carriers compared to wild-type patients.38, 39 It should be taken into account that 
our subgroup of AD patients was relatively small. Since the AD definition in our study 
population was based on ever having physician diagnosed AD before or at the age of 10 
year, some children might have outgrown their disease, which could have affected their 
immunophenotype. In addition, as we only measured immune cell numbers in the circula-
tion, we could therefore not exclude a migration of immune cells to the skin.40 Also in light 
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of these findings, we highlight that the pathogenesis of AD is highly complex with potential 
other genetic and environmental factors leading to skin barrier defects that might affect 
immune cell numbers in AD. Identifying differences in immune cell numbers in the skin 
and circulation in larger groups of individuals might help identify immune profiles based 
on FLG mutation status that could help to develop targeted therapies to prevent and/or 
treat the symptoms of AD in these subgroups.
nmF as biomarker for FLG mutation status in Ad
The exact mechanisms that lead to the transition from inherited barrier defect, caused by 
FLG mutations, to the clinical manifestations of inflammatory eczematous lesions remains 
to be fully elucidated. However, FLG mutations are a widely replicated major risk factor 
for AD and might be used both as a screening marker and as a prognostic biomarker for 
early onset, severe AD.41, 42 Considering that AD commonly affects children, the devel-
opment of non-invasive biomarkers are of added value. The NMF content in the SC of 
the thenar eminence has been proposed as biomarker to stratify patients based on FLG 
genotype.26, 43, 44 The SC of the thenar eminence is approximately 100µm, compared to a 
thickness of 10-15µm on the volar aspect of the arm. Therefore it regenerates less quickly 
and is thought to be less affected by acute changes in disease severity and to have more 
stable levels of NMF.45
In Chapter 5, we investigated the use of measuring NMF in the thenar eminence’s non-
lesional SC with Raman Spectroscopy as potential biomarker for FLG mutation status in a 
multi-ethnic population of 101 children with mild to severe AD. Raman spectroscopy can 
measure the NMF content in skin rapidly, non-invasively and provides an instant result. 
We concluded that the NMF content in the SC of the thenar eminence could accurately 
predict FLG mutation status (wild type vs ≥ 1 mutation) with an area under the curve of 
0.93 (95% CI 0.87-0.99). No correlation was found between acute disease severity and 
NMF content, thereby excluding a potential influence of acute disease severity on NMF 
values measured on the thenar eminence’s nonlesional skin. The cutoff value for NMF 
(1.03 a.u.), that was determined by maximizing of the sum of sensitivity and specificity 
(97% and of 87%, respectively), was highly comparable to a previous determined cutoff 
value in a selected AD cohort including children from Irish ancestry.43
Among the wild-type patients, 13% had low NMF content in the SC. These low NMF values 
in the SC of the thenar eminence were not associated with disease severity. Other factors 
that can influence the levels of NMF in the SC are FLG intragenetic copy number variation 
(CNV), protease activity (e.g. bleomycin hydrolase (BH) and Caspase 14) and humidity. 
46-49  Therefore we can argue that NMF measurement is potentially more useful to screen 
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for skin barrier defects than genetic analysis, because it measures the functional conse-
quences of all genetic and environmental factors that affect NMF production.
FuTure PersPecTiVes
investigating S. aureus gene expression and antibody responses in the pathogenesis 
of AD
Based on our results and previous literature, we assume that no specific strains of S. 
aureus colonize AD patients in comparison to healthy individuals. In addition, the majority 
of the AD patients is persistently colonized by the same S. aureus strain over the course 
of disease, varying from mild/stable disease to disease flare. Therefore it remains to be 
elucidated further how this bacterium can be present both as commensal organism and as 
pathogen leading to the symptoms of AD.7 We suggest two possible mechanisms that are 
of interest for future research.
First, it is possible that AD patients have an altered immunological response against S. 
aureus that causes the symptoms in AD. A previous publication found that AD patients 
more often had IgE antibody response against S. aureus superantigens compared to 
healthy controls.50 In addition, IgG mediated immune response against immune modulat-
ing S. aureus antigens was associated with disease severity in children with AD.51 As the 
antibody response was only directed towards a subset of S. aureus antigens rather than 
the entire range of antigens, these results suggest an altered immune response against 
specific antigens instead of a reflection of increased S. aureus load in AD.
A second possible mechanism is that S. aureus expresses different genes during different 
disease states. This varying gene expression provokes an altered immunological response 
leading to the symptoms of AD, varying from mild disease to disease flares and to the 
chronic phase characterized by lichenification. Cutaneous AD colonization models, in 
which mice were topically colonized with human S. aureus strains, have investigated 
the immunological response against 10 phylogenetically distinct S. aureus isolates from 
AD patients and controls.15 These results showed that cutaneous T-cell infiltration and 
increased epidermal thickening was a common response to S. aureus strains from patients 
with a more severe AD flares.15 In addition, sepsis models have investigated S. aureus gene 
expression during different disease states, ranging from asymptomatic colonization to 
bacteremia.52 Interestingly, during nasal colonization, adhesin genes were most commonly 
expressed, whereas upregulation of immune evasion and exotoxin genes were observed 




Until now, the differential expression of genes has not been proven for AD and studies 
investigating the immunological response against S. aureus are scarce. Therefore, it would 
be of interest to determine S. aureus gene expression and immunological responses over 
the course of disease and correlate this to the clinical symptoms in AD. This could lead to 
further insights into the working mechanisms and the pathogenic role of this bacterium in 
the heterogeneous phenotype of AD.
identify Ad patients who might benefit from targeted anti-S. aureus therapy
Based on our results from Chapter 3.2, it can be doubted whether topical endolysin treat-
ment is the most convenient strategy to target S. aureus on the skin. However, major 
drawbacks of currently available antimicrobial therapies (i.e., antibiotics and bleach 
baths) are the impact on the commensal microbiota and/or the development of bacte-
rial resistance.53-55 Therefore, it is desirable to develop and investigate pathogen-specific 
anti-staphylococcal agents for long-term use that do not cause resistance or harm the 
beneficial commensal microbiome. Novel targeting strategies are under investigation. 
Mouse models and pre-clinical trials showed reduced S. aureus colonization and disease 
severity after the application of topical coagulase-negative Staphylococcus (coNS) that 
produce highly potent antimicrobial peptides against S. aureus molecules.56, 57 Also other 
skin commensal species, vaccines and monoclonal antibodies (moAB) that neutralize one 
or more S. aureus toxins are being further investigated, but not yet available for clinical 
use.58, 59
It is of interest to identify patients that might benefit from these anti-staphylococcal 
agents. Current guidelines do not recommend anti-microbial treatment in clinically 
non-infected AD.60, 61 However, based on the results of this thesis we are of opinion that 
this heterogeneous group of clinically non-infected AD cannot be considered as a single 
entity. The symptoms can vary from mild symptoms to disease flares and S. aureus is also 
thought to contribute to the development of the chronic AD lesions that are characterized 
by lichenification.62 Therefore novel agents, including endolysins, that specifically target S. 
aureus should be investigated in subgroups of AD patients that are clearly defined based 
on phenotypic characteristics.
investigating the benefit of intranasal treatment in Ad
In addition to the skin, we suggest to further investigate the added value of pathogen-
specific anti-staphylococcal agents in different niches of the body. In Chapter 2 we showed 
high S. aureus colonization rates in the nose of patients with AD. In addition, up to 79% 
of the patients positive for S. aureus had identical spa-types in nose and skin, indicat-
ing a role for endogenous S. aureus transmission from nose to skin and/or vice versa. 
Intranasal treatment with mupirocin is common in hospitalized patients and has shown 
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to be successful in decolonizing other body sites and preventing infection in surgical and 
dialysis patients.63-65 A randomized placebo-controlled study observed that bleach baths in 
combination with intranasal mupirocin over the course of 3 months improved AD symp-
toms, compared to intranasal petrolatum ointment treatment and plain water baths.66 
Since other studies investigating the added value of intranasal anti-staphylococcal agents 
in AD are lacking, more research is needed.
The use of nMF in future association studies with FLG mutations in Ad
FLG genotype is the major determinant of NMF levels in the SC.67 However, reduced levels 
of NMF have been observed in both wild-type patients and FLG mutation carriers, mak-
ing skin barrier defects a common trait in AD.67, 68 Especially disease severity is thought 
to impact the levels of NMF in the SC through the increased presence of Th2 cytokines 
(IL-4 and IL-13).32 Also other mechanisms have impact on the levels of NMF, including FLG 
CNV, protease function, humidity and possible unknown mutations in other genes of the 
epidermal differentiation complex (EDC).46, 47 Therefore, it is of interest to investigate the 
relative impact of FLG mutations in future association studies. In line with this, we suggest 
to measure the functional consequences of the skin barrier defects (i.e., NMF) and correct 
for FLG genotype. The exact location for this measurement might depend on the research 
question as regional variations in NMF content have been described.69 For measuring local 
processes, including the microbiome on the skin surface, it would be relevant to measure 
NMF at the same location as the microbial swabs are collected. For more acute systemic 
processes, including circulating immune cell numbers, nonlesional skin is thought to have 
higher correlations with disease severity than lesional skin.70, 71 However, as it was recently 
shown that the amount of NMF varies in nonlesional skin, depending on distance from the 
eczematous skin lesion, there is need for standardization of the sampling location.72
Further determining the clinical utility of determining FLG mutation status in Ad
We have highlighted that FLG carriers are at increased risk to develop AD that is associated 
with early onset disease, increased AD severity and other allergic conditions (i.e., food 
allergies, asthma, and allergic rhinitis).20-22 The clinical utility of identifying children with 
a mutation in this gene needs to be further determined. We are only at the beginning 
of investigating whether AD patients with FLG mutations respond differently to available 
treatments.73, 74 Interventions to prevent the development of AD in these high risk children 
are lacking. Two large randomized controlled trials (RCTs) did not found evidence for daily 
emollient treatment in the first year of life to prevent AD in high-risk children (based on 
family history and FLG mutation status of the child).75, 76 In addition, AD children with FLG 
mutations are at increased risk to develop other allergic conditions. Early pro-active in-
terventions in this patient group might prevent the development of allergen sensitization 
and associated food allergy, asthma and allergic rhinitis.77 As we have argued that NMF 
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measurement is potentially more useful to screen for skin barrier defects than genetic 
analysis, clinical trials including both FLG mutation status and NMF measurement should 
further determine the translational value of these measurements.
integrating biomarkers related to the skin barrier, immune system and skin 
microbiome
Besides a non-invasive biomarker to determine FLG mutation status, there is need for the 
development of other biomarkers. Especially in a disease such as AD with a complex and 
heterogeneous pathophysiology and clinical presentation, it is unlikely that currently avail-
able and newly developed highly specific treatments are effective in all AD patients. This 
thesis highlighted that a defect in one of the three main pathological aspects, including the 
skin microbiome, skin barrier and immune system, is not likely to cause disease on its own. 
Alterations in all three aspects and their interactions contribute to the pathogenesis of AD 
and are likely to differ per patient and might also change over the lifetime of an individual. 
For instance, not all patients are carrier of a FLG mutation and not all patients are colonized 
by S. aureus. By defining subgroups of patients, based on the underlying disease pathways, 
we can stratify this highly heterogeneous disease into endotypes for more personalized 
care. Previous research has identified clusters with distinct serum biomarker profiles and 
overlapping clinical phenotypes that represented distinct disease endotypes.78 They could 
identify clusters that shared a Th2 cytokine–low and pauci-inflammatory mediator state 
presenting with a greater frequency of the lichenified skin phenotype.78 These patients 
would hypothetically benefit less from Th2-targeting agents. Adding S. aureus abundance, 
S. aureus gene expression profiles, skin barrier parameters and immunological parameters 
in these models and associate clusters with clinical characteristics could identify the un-
derlying pathophysiologic processes and identify targets for personalized treatment. The 
next step would be to perform clinical intervention trials to evaluate treatment targeting 
patient specific disease pathways.
concludinG reMArks
This thesis shows that the microbiome, characterized by an increased S. aureus abun-
dance, is an important aggravating factor in AD. The majority of the patients with AD 
remains colonized with the same S. aureus strain over time in both nose and skin. Since 
the colonizing strains are not unique for AD patients, we hypothesize that this bacterium 
exerts its effect through increased abundance, gene expression and the immunological 
response towards it. Another common trait in AD patients, is the impairment of the skin 
barrier that can be associated with FLG mutations in up to 40% of the patients. Muta-
tions in this gene are associated with a more severe phenotype and appear to affect the 
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overall microbiome in these patients. Although not confirmed in this thesis, the increased 
penetration of external stimuli is likely to provoke a different immunological response 
compared to wild-type patients. Multiple other genetic and environmental factors affect 
the filaggrin expression in the SC, resulting in lower levels of NMF. By measuring both NMF 
levels and FLG mutations we might determine the relative impact of FLG mutation status 
on the microbiome and immune cell numbers.
Our findings highlight that the pathogenesis of AD cannot be explained by only one 
mechanism but involves interactions between the skin microbiome, skin barrier and 
immune system. It is of interest to further investigate these interactions to establish a 
more comprehensive disease model for AD. Large patient groups with patients of different 
ages and ethical backgrounds are necessary. Last, we advise to further define subgroups 
of patients based on the underlying disease pathways to enable personalized treatment. 
More than individual biomarkers, a combination of different biomarkers related to the 
skin microbiome, skin barrier and immune system can be used for the stratification of this 
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chapter 1 is a general introduction describing the main objectives of this thesis. Atopic 
dermatitis (AD), also known as eczema, is a chronic inflammatory skin disease which affects 
up to 20% of children and 10% of adults in developed countries. This disorder is character-
ized by recurrent eczematous lesions and intense itch, which have a great impact on the 
quality of life. The cause of AD is a complex interplay between microbiome abnormalities, 
an impaired skin barrier and immune dysregulation. Currently, there is no cure for AD and 
therapy is focused on disease control. For a better understanding of this disease, we aimed 
to further investigate these three factors that contribute to the pathogenesis of AD and 
to assess how they interact with each other. In particular, we focused on the role of the 
microbiome (with the predominance of Staphylococcus (S.) aureus) and the skin barrier 
defect (caused by mutations in the gene encoding filaggrin (FLG)). These insights will help 
us develop new treatment strategies to reduce the symptoms of AD.
Especially the skin (lesional and nonlesional) and the nasal cavity of AD patients are fre-
quently colonized by S. aureus, which adversely affects disease severity. Although, with 
lower prevalence, healthy controls can also be colonized with this bacterium. It remains 
largely unknown how S. aureus can be present on the skin both as a commensal organ-
ism and as a pathogen causing inflammation characteristic of AD. It has been suggested 
that AD patients are colonized by genetically different S. aureus strains, as compared to 
non-AD individuals. Therefore, in chapter 2, we aimed to investigate whether AD patients 
are colonized by specific S. aureus strains and if certain strains are associated with more 
severe disease. For this purpose, we performed a longitudinal study that included 96 adult 
AD patients with moderate to severe disease. Spa-typing was performed on S. aureus 
isolates from the nose and skin that were collected over the course of two weeks. The 
spa-typing technique discriminates between different S. aureus strains by determining the 
DNA sequence of the S. aureus-specific Staphylococcal protein A (spa) gene. Our results 
showed that there is large inter-individual variation in spa-types, that is similar to non-AD 
individuals. In addition, we concluded that the intra-individual variation is minor, with 
the majority of the individual patients being colonized by the same spa-type in both nose 
and skin and over a period of time. No predominant spa-type nor temporal variation in 
spa-types was associated with more severe disease. The presence of a certain strain is 
likely influenced by host genetic and environmental factors.
Mutations in FLG lead to reduced expression of the protein filaggrin that is essential in 
the development and maintenance of the skin barrier. Individuals with a mutation in this 
gene are at increased risk to develop a form of AD that starts in early infancy, persists into 
adulthood and is associated with increased disease severity and the development of other 
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allergic conditions (i.e., food allergies, asthma and allergic rhinitis). The exact mechanisms 
contributing to this disease modification effect are largely unknown. It is thought that 
FLG mutations lead to alterations in the skin microbiome and circulating immune cell 
numbers. In chapter 3.1 we aimed to investigate the effect of FLG mutation status (wild 
type versus ≥ 1 mutation in FLG) on the microbial composition in a cross-sectional study 
including 77 children with difficult to treat AD. All patients were screened for mutations 
in FLG and the microbiome of the nose, lesional and nonlesional skin was characterized 
using 16S rRNA sequencing. Instead of only screening for the most common mutations 
in Western-European populations, as done in previous research, the entire encoding 
region of FLG was screened to detect loss of function mutations. This new approach led 
to an improvement of the diagnostic yield, since it enables to detect novel, family- and 
population specific mutations. We showed that the nose, lesional skin and nonlesional 
skin harbored different microbial communities. In addition, we concluded that the overall 
microbiome was affected by the presence of a mutation in FLG. These results propose 
interactions between host genetics and the microbiome. Since literature on this subject 
is scarce, more studies including larger patient groups are of interest. In chapter 3.2, 
we explored the effect of mutations in FLG on the circulating immune cells (T- and B-cell 
subsets at the age of 10 years) in 523 children of the general population and a subgroup 
of 102 children with AD. This research was part of a large prospective birth cohort study 
of Generation R, Rotterdam. We established that the presence of a mutation in FLG was 
associated with higher T helper (Th)22 cells in children of the general population, but not 
with other T- and B-cell subsets. In the subgroup of children with AD, FLG mutations did 
not affect the circulating immune cell numbers. Since Th22 is involved in the skin barrier 
integrity and in the defense against pathogens, we hypothesized that the upregulation of 
Th22 is an immunological defense mechanism against an altered skin barrier function in 
children of the general population.
Filaggrin is degraded into free amino acids in the stratum corneum (SC) of the skin. The 
amino acids and their derivatives form the largest part of the natural moisturizing factor 
(NMF). NMF plays an important role in skin hydration, maintenance of the skin pH and 
ultra-violet (UV) protection. It has been suggested that the concentrations of NMF in the 
SC could predict the presence of FLG mutations in patients with AD. In chapter 4, we 
assessed if the NMF content in the SC of the thenar eminence (nonlesional) could be used 
as a valid biomarker to stratify AD patients according to FLG mutation status. This research 
was conducted in a multi-ethnic pediatric AD cohort. The entire encoding region of FLG 
was screened for mutations in 101 AD children. NMF was measured using Raman Spec-
troscopy, a non-invasive optical technique based on light scattering from molecules in the 
skin. We showed that the NMF content in the SC could accurately stratify patients based 
on FLG mutation status with high sensitivity and specificity, without direct interference 
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of present disease severity. NMF measurement can be used in daily practice to identify 
patients with high risk for a more severe AD phenotype caused by a mutation in FLG.
chapter 5 focused on treatment interacting with the skin microbiome to improve AD 
related symptoms. In chapter 5.1, we studied the effects of alpine climate treatment on 
the microbiome of 79 children with difficult to treat AD. Alpine climate treatment has 
been used to treat patients with AD and/or asthma. This climate is characterized by low 
exposure to allergens, pollutants and increased UV radiation. We described the secondary 
outcomes of a pragmatic randomized controlled trial in which patients were randomized 
to a six-week treatment period either in an alpine clinic in Switzerland or in an outpatient 
setting in the Netherlands. It was previously shown that children in the alpine climate 
group had a significantly greater improvement in disease severity, compared to children in 
the moderate maritime climate group. In contrast to treatment in the Netherlands, alpine 
climate treatment led to a significant change in the microbiome on lesional skin. In addi-
tion, the S. aureus load on both lesional and nonlesional skin decreased after treatment 
in alpine climate. This study showed that alpine climate treatment leads to changes in the 
skin microbiome, reflecting the successful treatment. We encourage further investigation 
of skin microbiome modulating therapies to improve the symptoms of AD. In chapter 
5.2 we presented the outcomes of a randomized vehicle-controlled trial that studied the 
effect of topical treatment with an endolysin targeting S. aureus in 100 adult patients 
with non-infected AD. The advantage of specifically targeting S. aureus with an endolysin, 
as compared to current available anti-microbial agents (i.e., antibiotics), is that it does 
not lead to bacterial resistance and does not affect other commensal micro-organisms. 
The results showed that endolysin treatment was safe and well tolerated. No significant 
differences were found in the use of topical corticosteroid (TCS) between the endolysin 
and vehicle treated groups, nor in the reduction of clinical disease severity scores. In 
line with these clinical outcomes, no significant reduction was observed in the S. aureus 
load on the skin. This lack of difference might be explained by the significant decrease in 
disease severity that was achieved in the run-in-phase of this trial, in which treatment 
was standardized with topical corticosteroids and emollients. The methodological lessons 
learned can be used for future clinical studies that evaluate treatment in AD.
Finally, in chapter 6 we presented a general overview of the main findings considering the 
limitations of our research and propose directions for future research. We concluded that 
the pathogenesis of AD cannot be explained by only one mechanism, but involves multiple 
interactions between the skin microbiome, skin barrier and immune system. As the role of 
the three elements is likely to differ per patient and over the lifetime of an individual, we em-
phasized to further identify subgroups of patients based on the underlying disease pathways. 




hoofdstuk 1 is een algemene introductie met een beschrijving van de belangrijkste 
doelstellingen van dit proefschrift. Constitutioneel eczeem (CE) is een chronische inflam-
matoire huidziekte die tot 20% van de kinderen en tot 10% van de volwassenen treft in 
Westerse landen. Deze aandoening wordt gekenmerkt door recidiverende eczemateuze 
laesies en hevige jeuk, welke een grote impact hebben op de kwaliteit van leven. CE 
wordt veroorzaakt door een complex samenspel tussen afwijkingen in het microbioom, 
een verminderde huidbarrière en immuundysregulatie. Tot op heden is er geen remedie 
voor CE en is de behandeling gericht op het bestrijden van symptomen. Wij stelden ons 
ten doel om meer inzicht te krijgen in de drie bovengenoemde factoren die betrokken 
zijn in de pathogenese van CE en te onderzoeken hoe ze met elkaar interacteren. In het 
bijzonder hebben wij ons geconcentreerd op de rol van het microbioom (gedomineerd 
door Staphylococcus (S.) aureus) en het huidbarrière defect (veroorzaakt door mutaties in 
het filaggrine gen (FLG)). Deze inzichten zullen ons helpen bij de ontwikkeling van nieuwe 
behandelingsstrategieën om de symptomen van CE te verlichten.
Met name de huid (aangedane en niet aangedane) en de neusholte van CE-patiënten zijn 
vaak gekoloniseerd met S. aureus, wat de ernst van de ziekte nadelig beïnvloedt. Ook 
gezonde individuen kunnen gekoloniseerd zijn met deze bacterie. Het blijft grotendeels 
onbekend hoe S. aureus zowel een commensaal organisme kan zijn als een ziekteverwek-
ker die bijdraagt aan de symptomen van CE. In hoofdstuk 2 stelden we ons ten doel te 
onderzoeken of patiënten met CE gekoloniseerd zijn door specifieke S. aureus stammen 
en of bepaalde stammen geassocieerd zijn met ernstigere klachten van CE. Met dit doel 
hebben wij een longitudinale studie uitgevoerd waaraan 96 CE patiënten deelnamen met 
matig tot ernstige ziekte. Spa-typering werd uitgevoerd op S. aureus-kweken van de neus 
en huid, die in de loop van twee weken werden verzameld. De spa-typeringstechniek 
maakt onderscheid tussen verschillende S. aureus stammen door de DNA-sequentie van 
het S. aureus-specifieke Staphylococcal proteïne A (spa) gen te bepalen. Onze resultaten 
toonden dat er in de bestudeerde CE-populatie een grote inter-individuele variatie is in 
spa-typen, welke vergelijkbaar is met individuen zonder CE. Daarnaast vonden we dat de 
intra-individuele variatie gering is, waarbij de meerderheid van de individuele CE patiën-
ten gekoloniseerd is met hetzelfde spa-type zowel in de neus als op de huid en over een 
periode van tijd. Er was geen verband tussen de ernst van de ziekte en de aanwezigheid 
van een bepaald spa-type. We veronderstellen dat de aanwezigheid van een specifieke 
stam vooral wordt beïnvloed door genetische -en omgevingsfactoren van het individu.
Mutaties in FLG leiden tot verminderde expressie van het eiwit filaggrine dat essentieel 
is voor de ontwikkeling en het behoud van de huidbarrière. Individuen met een muta-
189
Summary / Samenvatting
tie in dit gen lopen een verhoogd risico op het ontwikkelen van een vorm van CE die 
al op jonge leeftijd begint, aanhoudt tot op volwassen leeftijd en gepaard gaat met een 
ernstiger ziektebeeld en de ontwikkeling van andere allergische aandoeningen (voedselal-
lergieën, astma en allergische rhinitis). De exacte mechanismen die hieraan bijdragen zijn 
grotendeels onbekend. Er wordt gedacht dat FLG mutaties leiden tot veranderingen in 
het huid-microbioom en het aantal circulerende immuuncellen. In hoofdstuk 3.1 heb-
ben we onderzocht of patiënten met ≥1 mutatie in FLG een andere samenstelling van het 
microbioom hebben in vergelijking met patiënten zonder een mutatie in dit gen. Met dit 
doel werd een cross-sectionele studie uitgevoerd waarin 77 kinderen met moeilijk behan-
delbaar CE werden geïncludeerd. FLG werd gescreend op mutaties en het microbioom 
van de neus, de aangedane en niet aangedane huid werd in kaart gebracht met behulp 
van 16S rRNA sequencing. In plaats van te screenen op de meest voorkomende mutaties 
in West-Europese populaties, wat veelal is gedaan in eerder onderzoek, werd de gehele 
coderende regio van FLG gescreend op mutaties. Deze techniek verbetert de diagnostische 
opbrengst in vergelijking met het alleen bepalen van populatie-specifieke mutaties. Dit is 
te verklaren doordat hierbij ook zeldzame, familie specifieke, en niet eerder beschreven 
mutaties worden gedetecteerd. Daarnaast toonden onze resultaten dat het microbioom 
verschillend is per afnamelocatie (neus, de aangedane en niet aangedane huid) en dat de 
samenstelling wordt beïnvloed door de aanwezigheid van een FLG mutatie. Deze resulta-
ten suggereren een wisselwerking tussen genetische factoren en het microbioom. Er zijn 
studies met grotere patiëntengroepen nodig om deze resultaten te bevestigen. In hoofd-
stuk 3.2 onderzochten we het effect van mutaties in FLG op de circulerende immuuncellen 
(T -en B-cellen op de leeftijd van 10 jaar) in een algemene pediatrische populatie (n=523) 
en een subgroep van 102 kinderen met CE. Het onderzoek maakt deel uit van een groot-
schalig geboorte cohortstudie in Rotterdam, genaamd Generation R. We toonden aan dat 
de aanwezigheid van een mutatie in FLG is geassocieerd met hogere aantallen T helper 
(Th)22 cellen in kinderen van de algemene populatie, maar niet met andere T -en B-cellen. 
De aanwezigheid van een FLG mutatie had geen invloed op hoeveelheid immuuncellen in 
een subgroep van kinderen met CE. Th22 speelt een rol in de integriteit van de huidbar-
rière en de verdediging tegen ziekteverwekkers. Dit veronderstelt dat de toename van 
Th22 een verdedigingsmechanisme is van het afweersysteem tegen een verminderde 
huidbarrièrefunctie in een algemene pediatrische populatie.
Filaggrine wordt in de hoornlaag van de huid afgebroken tot vrije aminozuren. De ami-
nozuren en hun derivaten vormen samen het grootste deel van de ‘natural moisterizing 
factor’ (NMF). NMF speelt een belangrijke rol bij de hydratatie van de huid, de instandhou-
ding van de pH-waarde en de bescherming tegen ultraviolet licht (UV). Eerder onderzoek 
suggereerde dat de hoeveelheid NMF in de hoornlaag de aanwezigheid van FLG mutaties 
bij patiënten met CE zou kunnen voorspellen. In hoofdstuk 4 beoordeelden we of de hoe-
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veelheid NMF in de hoornlaag van de huid op de duimmuis gebruikt kan worden als bio-
marker in CE om patiënten te stratificeren op basis van FLG mutatie status. Dit onderzoek 
werd uitgevoerd in een multi-etnisch cohort van kinderen met CE. De gehele coderende 
regio van FLG werd gescreend op mutaties in 101 CE kinderen. De hoeveelheid NMF werd 
gemeten met Raman Spectroscopy. Dit is een niet-invasieve techniek gebaseerd op de 
weerkaatsing van invallend licht door moleculen in de huid. We concludeerden dat de 
hoeveelheid NMF kan worden gebruikt als biomarker om patiënten te stratificeren op ba-
sis van FLG mutatie status met hoge sensitiviteit en specificiteit, zonder directe inmenging 
van de actuele ziekte-ernst. De NMF-meting kan in de dagelijkse praktijk worden gebruikt 
om patiënten te identificeren met een hoog risico op een ernstiger CE fenotype veroor-
zaakt door een mutatie in FLG.
hoofdstuk 5 richt zich op behandelingen die interacteren met het microbioom van de 
huid met als doel de klachten van CE te verlichten. In hoofdstuk 5.1 bestudeerden we de 
effecten van hooggebergtebehandeling op het microbioom van 79 kinderen met moeilijk 
behandelbaar CE. Hooggebergtebehandeling kan gebruikt worden voor de behandeling 
van patiënten met CE en/of astma. Dit klimaat wordt gekenmerkt door een lage blootstel-
ling aan allergenen, verontreinigende stoffen en verhoogde UV-straling. We beschrijven 
de secundaire uitkomsten van een pragmatische gerandomiseerde gecontroleerde studie 
waarin patiënten werden gerandomiseerd voor een 6 weekse behandelperiode in een kli-
niek in het hooggebergte in Zwitserland of poliklinisch behandeling in gematigd zeeklimaat 
in Nederland. In deze studiepopulatie werd eerder aangetoond dat er significant meer 
verbetering was in ziekteactiviteit in de hooggebergte groep. In tegenstelling tot de be-
handeling in Nederland leidde hooggebergtebehandeling tot een significante verandering 
in het microbioom op de aangedane huid. Bovendien nam de hoeveelheid S. aureus op de 
aangedane en niet aangedane huid af na behandeling in hooggebergte. Deze studie toont 
aan dat hooggebergtebehandeling leidt tot veranderingen in het microbioom van de huid, 
wat de succesvolle behandeling weerspiegelt. We moedigen verder onderzoek aan naar 
therapieën die het microbioom van de huid kunnen moduleren om de symptomen van CE 
te verlichten. In hoofdstuk 5.2 evalueerden we de werkzaamheid en veiligheid van een op 
endolysine gebaseerde therapie gericht op de S. aureus bacterie in een gerandomiseerde 
gecontroleerde studie met 100 volwassen patiënten met niet-geïnfecteerd CE. Het voor-
deel van het specifiek aanpakken van S. aureus met een endolysine, in vergelijking met de 
huidige beschikbare antimicrobiële middelen (zoals antibiotica), is dat het niet leidt tot 
bacteriële resistentie en geen invloed heeft op andere commensale micro-organismen. 
De resultaten toonden aan dat de behandeling met endolysine veilig was en goed werd 
verdragen. Er werd geen significant verschil gevonden in het gebruik van topicale cortico-
steroïden (TCS) tussen de met endolysine en placebo behandelde groepen. Daarnaast was 
er geen verschil in de scores voor de ernst van de ziekte. In overeenstemming met deze 
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klinische resultaten werd geen significante vermindering waargenomen in de hoeveelheid 
S. aureus op de huid. Het uitgebleven voordeel van endolysine behandeling is mogelijk te 
verklaren door de significante afname in ziekte-ernst in de aanloopfase van dit onderzoek, 
waarin de behandeling werd gestandaardiseerd met TCS en vette zalf. De geleerde me-
thodologische lessen kunnen gebruikt worden voor toekomstige klinische studies die het 
effect van behandeling evalueren in CE.
Tot slot presenteerden we in hoofdstuk 6 een algemeen overzicht van de belangrijkste 
bevindingen van dit proefschrift waarbij we de methodologische beperkingen in acht 
nemen. Daarnaast doen we suggesties voor toekomstig onderzoek. Wij concludeerden 
dat de pathogenese van CE niet kan worden verklaard door slechts één mechanisme, 
maar dat er meerdere interacties zijn tussen het huid-microbioom, de huidbarrière en 
het immuunsysteem. Wij veronderstellen op basis van onze resultaten dat de rol van deze 
drie elementen verschilt per patiënt en ook kan veranderen over de levensloop van een 
patiënt. Door het bepalen van microbiële, epidermale en immunologische biomarkers 
kunnen we subgroepen van patiënten met CE identificeren op basis van de onderliggende 
ziektemechanismen. Met behulp van deze methode kunnen we deze heterogene ziekte 



















Minke M.F. van Mierlo
TH
E M
ICRO
BIO
M
E AN
D
 TH
E SKIN
 BARRIER IN
 ATO
PIC D
ERM
ATITIS
M
inke M
.F. van M
ierlo
TH
E M
ICRO
BIO
M
E AN
D
 TH
E SKIN
 BARRIER IN
 ATO
PIC D
ERM
ATITIS
TH
E M
ICRO
BIO
M
E AN
D
 TH
E SKIN
 BARRIER IN
 ATO
PIC D
ERM
ATITIS
TH
E M
ICRO
BIO
M
E AN
D
 TH
E SKIN
 BARRIER IN
 ATO
PIC D
ERM
ATITIS
TH
E M
ICRO
BIO
M
E AN
D
 TH
E SKIN
 BARRIER IN
 ATO
PIC D
ERM
ATITIS
TH
E M
ICRO
BIO
M
E AN
D
 TH
E SKIN
 BARRIER IN
 ATO
PIC D
ERM
ATITIS
M
inke M
.F. van M
ierlo
M
inke M
.F. van M
ierlo
M
inke M
.F. van M
ierlo
M
inke M
.F. van M
ierlo
M
inke M
.F. van M
ierlo
